Modulation	O
of	O
E2F	B-protein
complexes	I-protein
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
.	O

The	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	B-protein
protein-E2F	I-protein
complexes	I-protein
in	O
human	B-cell_type
primary	I-cell_type
B-lymphocytes	I-cell_type
after	O
activation	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Consistent	O
with	O
previous	O
data	O
from	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
fibroblasts	I-cell_type
and	O
T-lymphocytes	B-cell_type
,	O
E2F4	B-protein
and	O
DP1	B-protein
form	O
the	O
predominant	O
E2F	B-protein
heterodimers	I-protein
both	O
in	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
human	O
B-lymphocyte	O
cell	O
cycle	O
,	O
whereas	O
E2F1	B-protein
and	I-protein
-3	I-protein
are	O
first	O
detected	O
in	O
late	O
G1	O
,	O
and	O
their	O
expression	O
levels	O
increase	O
towards	O
S	O
phase	O
.	O

Intriguingly	O
,	O
the	O
major	B-protein
E2F	I-protein
complex	I-protein
that	O
we	O
detected	O
in	O
quiescent	B-cell_type
human	I-cell_type
B-lymphocytes	I-cell_type
is	O
consisted	O
of	O
pRB	B-protein
,	O
E2F4	B-protein
,	O
and	O
DP1	B-protein
.	O

Though	O
the	O
levels	O
of	O
DP1	B-protein
and	I-protein
-2	I-protein
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B-protein
to	O
DP2	B-protein
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O

We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B-protein
components	I-protein
,	O
DP1	B-protein
and	O
E2F4	B-protein
,	O
as	O
B-lymphocytes	B-cell_type
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O

This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	B-protein
migrating	I-protein
forms	I-protein
into	O
the	O
corresponding	B-protein
faster	I-protein
mobility	I-protein
forms	I-protein
.	O

We	O
further	O
demonstrated	O
that	O
this	O
change	O
in	O
phosphorylation	O
status	O
correlates	O
with	O
a	O
decrease	O
in	O
DNA	O
binding	O
activity	O
.	O

This	O
modulation	O
of	O
DNA	O
binding	O
activity	O
mediated	O
through	O
the	O
dephosphorylation	O
of	O
DP1	B-protein
and	O
E2F4	B-protein
could	O
help	O
to	O
explain	O
the	O
lack	O
of	O
in	O
vivo	O
DNA	O
footprinting	O
in	O
late	O
G1	O
and	O
S	O
phases	O
of	O
gene	B-DNA
promoters	I-DNA
negatively	O
regulated	O
through	O
E2F	B-DNA
sites	I-DNA
and	O
suggests	O
a	O
novel	O
mechanism	O
for	O
controlling	O
E2F	B-protein
transcriptional	O
activity	O
during	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferation	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

17	NULL
,	NULL
Issue	NULL
of	NULL
April	NULL
23	NULL
,	NULL
pp	NULL
.	NULL

12009-12016	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Modulation	NULL
of	NULL
E2F	NULL
Complexes	NULL
during	NULL
G	NULL
,	NULL
to	NULL
S	NULL
Phase	NULL
Transition	NULL
in	NULL
Human	NULL
Primary	NULL
B-lymphocytes*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
October	NULL
21	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
January	NULL
27	NULL
,	NULL
1999	NULL
)	NULL
Jeroen	NULL
van	NULL
der	NULL
Smant	NULL
,	NULL
N.	NULL
Shaun	NULL
B.	NULL
Thomas	NULL
$	NULL
§1	NULL
,	NULL
and	NULL
Eric	NULL
W.-F.	NULL
Lam	NULL
#	NULL
]	NULL
From	NULL
the	NULL
{	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
and	NULL
Section	NULL
of	NULL
Virology	NULL
and	NULL
Cell	NULL
Biology	NULL
,	NULL
Imperial	NULL
College	NULL
School	NULL
of	NULL
Medicine	NULL
at	NULL
St	NULL
Mary	NULL
's	NULL
,	NULL
London	NULL
W2	NULL
1PG	NULL
and	NULL
§Department	NULL
of	NULL
Haematology	NULL
,	NULL
University	NULL
College	NULL
London	NULL
Medical	NULL
School	NULL
,	NULL
London	NULL
WC1E	NULL
6HX	NULL
,	NULL
United	NULL
Kingdom	NULL
The	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
are	NULL
convergence	NULL
points	NULL
for	NULL
cell	NULL
cycle	NULL
signaling	NULL
.	NULL

In	NULL
the	NULL
present	NULL
report	NULL
,	NULL
we	NULL
identified	NULL
and	NULL
monitored	NULL
the	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
in	NULL
human	NULL
primary	NULL
B-lymphocytes	NULL
after	NULL
activation	NULL
by	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
data	NULL
from	NULL
human	NULL
and	NULL
mouse	NULL
fibroblasts	NULL
and	NULL
T-lymphocytes	NULL
,	NULL
E2F4	NULL
and	NULL
DP1	NULL
form	NULL
the	NULL
predominant	NULL
E2F	NULL
heterodimers	NULL
both	NULL
in	NULL
G	NULL
,	NULL
and	NULL
G	NULL
,	NULL
phases	NULL
of	NULL
the	NULL
human	NULL
B-lymphocyte	NULL
cell	NULL
cycle	NULL
,	NULL
whereas	NULL
E2F1	NULL
and	NULL
-3	NULL
are	NULL
first	NULL
detected	NULL
in	NULL
late	NULL
G	NULL
,	NULL
,	NULL
and	NULL
their	NULL
expression	NULL
levels	NULL
increase	NULL
towards	NULL
S	NULL
phase	NULL
.	NULL

Intriguingly	NULL
,	NULL
the	NULL
major	NULL
E2F	NULL
complex	NULL
that	NULL
we	NULL
detected	NULL
in	NULL
quiescent	NULL
human	NULL
B-lymphocytes	NULL
is	NULL
consisted	NULL
of	NULL
pRB	NULL
,	NULL
E2F4	NULL
,	NULL
and	NULL
DPI	NULL
.	NULL

Though	NULL
the	NULL
levels	NULL
of	NULL
DPI	NULL
and	NULL
-2	NULL
increase	NULL
when	NULL
cells	NULL
progress	NULL
from	NULL
G	NULL
,	NULL
,	NULL
to	NULL
S	NULL
,	NULL
the	NULL
proportion	NULL
of	NULL
DPI	NULL
to	NULL
DP2	NULL
remains	NULL
relatively	NULL
constant	NULL
during	NULL
the	NULL
cell	NULL
cyele	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
an	NULL
increase	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
predominant	NULL
E2F	NULL
components	NULL
,	NULL
DPI	NULL
and	NULL
E2F4	NULL
,	NULL
as	NULL
B-lymphocytes	NULL
progressed	NULL
from	NULL
G	NULL
,	NULL
,	NULL
into	NULL
early	NULL
G	NULL
,	NULL
.	NULL

This	NULL
increase	NULL
in	NULL
mobility	NULL
was	NULL
attributable	NULL
to	NULL
dephosphorylation	NULL
,	NULL
as	NULL
A	NULL
phosphatase	NULL
treatment	NULL
could	NULL
convert	NULL
the	NULL
slower	NULL
migrating	NULL
forms	NULL
into	NULL
the	NULL
corresponding	NULL
faster	NULL
mobility	NULL
forms	NULL
.	NULL

We	NULL
further	NULL
demonstrated	NULL
that	NULL
this	NULL
change	NULL
in	NULL
phosphorylation	NULL
status	NULL
correlates	NULL
with	NULL
a	NULL
decrease	NULL
in	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

This	NULL
modulation	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
mediated	NULL
through	NULL
the	NULL
dephosphorylation	NULL
of	NULL
DPI	NULL
and	NULL
E2F4	NULL
could	NULL
help	NULL
to	NULL
explain	NULL
the	NULL
lack	NULL
of	NULL
in	NULL
vive	NULL
DNA	NULL
footprinting	NULL
in	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
of	NULL
gene	NULL
promoters	NULL
negatively	NULL
regulated	NULL
through	NULL
E2F	NULL
sites	NULL
and	NULL
suggests	NULL
a	NULL
novel	NULL
mechanism	NULL
for	NULL
controlling	NULL
E2F	NULL
transcriptional	NULL
activity	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
quiescence	NULL
to	NULL
proliferation	NULL
.	NULL

E2F	NULL
is	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
controls	NULL
cell	NULL
proliferation	NULL
through	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
essential	NULL
genes	NULL
required	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
1-4	NULL
)	NULL
.	NULL

The	NULL
E2F	NULL
transcription	NULL
factor	NULL
consists	NULL
of	NULL
one	NULL
protein	NULL
subunit	NULL
encoded	NULL
by	NULL
the	NULL
E2F	NULL
family	NULL
of	NULL
genes	NULL
and	NULL
the	NULL
other	NULL
by	NULL
the	NULL
DP	NULL
gene	NULL
family	NULL
,	NULL
and	NULL
to	NULL
date	NULL
,	NULL
six	NULL
distinct	NULL
E2F	NULL
(	NULL
E2F1I-6	NULL
)	NULL
and	NULL
two	NULL
DP	NULL
(	NULL
DPI-2	NULL
)	NULL
genes	NULL
have	NULL
been	NULL
cloned	NULL
from	NULL
mammalian	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
.	NULL

The	NULL
E2F	NULL
and	NULL
DP	NULL
proteins	NULL
cooperate	NULL
to	NULL
bind	NULL
DNA	NULL
and	NULL
activate	NULL
transcription	NULL
of	NULL
target	NULL
genes	NULL
in	NULL
a	NULL
synergistic	NULL
manner	NULL
(	NULL
2	NULL
)	NULL
.	NULL

E2F	NULL
activity	NULL
is	NULL
negatively	NULL
regulated	NULL
through	NULL
interactions	NULL
with	NULL
the	NULL
retinoblastoma	NULL
protein	NULL
(	NULL
pRB	NULL
)	NULL
family	NULL
of	NULL
``	NULL
pocket	NULL
proteins	NULL
,	NULL
``	NULL
consisting	NULL
of	NULL
pRB	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1784	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

4	NULL
]	NULL
Supported	NULL
by	NULL
the	NULL
Kay	NULL
Kendall	NULL
Leukaemia	NULL
Trust	NULL
.	NULL

|	NULL
Supported	NULL
by	NULL
the	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
and	NULL
the	NULL
Leukaemia	NULL
Research	NULL
Fund	NULL
.	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
ad-dressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
44-171-724-5522	NULL
(	NULL
ext	NULL
.	NULL

220	NULL
)	NULL
;	NULL
Fax	NULL
:	NULL
44-171-724-8586	NULL
;	NULL
E-mail	NULL
:	NULL
eric.lam	NULL
@	NULL
ic.ac.uk	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
p130	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Although	NULL
all	NULL
three	NULL
pocket	NULL
proteins	NULL
repress	NULL
EZF-de-pendent	NULL
transcription	NULL
(	NULL
6-9	NULL
)	NULL
,	NULL
individual	NULL
pocket	NULL
proteins	NULL
bind	NULL
preferentially	NULL
to	NULL
particular	NULL
subsets	NULL
of	NULL
E2F	NULL
family	NULL
members	NULL
.	NULL

Thus	NULL
,	NULL
pRB	NULL
interacts	NULL
exclusively	NULL
with	NULL
E2F1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
(	NULL
10	NULL
)	NULL
,	NULL
p107	NULL
binds	NULL
predominately	NULL
to	NULL
E2F4	NULL
,	NULL
and	NULL
p130	NULL
binds	NULL
specifically	NULL
to	NULL
both	NULL
E2F4	NULL
and	NULL
-5	NULL
(	NULL
6-9	NULL
,	NULL
11-14	NULL
)	NULL
.	NULL

Unlike	NULL
E2F1-5	NULL
,	NULL
the	NULL
newly	NULL
identified	NULL
member	NULL
of	NULL
the	NULL
E2F	NULL
protein	NULL
family	NULL
,	NULL
E2FG6	NULL
,	NULL
does	NULL
not	NULL
possess	NULL
an	NULL
equivalent	NULL
pocket	NULL
protein	NULL
binding	NULL
domain	NULL
and	NULL
therefore	NULL
does	NULL
not	NULL
interact	NULL
with	NULL
the	NULL
pRB	NULL
family	NULL
of	NULL
proteins	NULL
in	NULL
the	NULL
same	NULL
manner	NULL
as	NULL
other	NULL
E2Fs	NULL
.	NULL

The	NULL
functional	NULL
role	NULL
of	NULL
E2F6	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
fully	NULL
established	NULL
,	NULL
but	NULL
the	NULL
protein	NULL
is	NULL
believed	NULL
to	NULL
act	NULL
as	NULL
a	NULL
repressor	NULL
for	NULL
E2F-dependent	NULL
transcription	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
E2F	NULL
binding	NULL
sites	NULL
can	NULL
regulate	NULL
cell	NULL
cycle-dependent	NULL
transcription	NULL
through	NULL
acting	NULL
as	NULL
transcriptional	NULL
activators	NULL
and/or	NULL
repressors	NULL
during	NULL
different	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
B-myb	NULL
,	NULL
E2F1	NULL
,	NULL
E2F2	NULL
,	NULL
cyclin	NULL
E	NULL
and	NULL
cde2	NULL
promoter	NULL
activity	NULL
appears	NULL
to	NULL
be	NULL
cell	NULL
cycle-regulated	NULL
predominantly	NULL
by	NULL
repression	NULL
through	NULL
the	NULL
E2F	NULL
binding	NULL
site	NULL
during	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
(	NULL
18-24	NULL
)	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
DHFR	NULL
transcription	NULL
is	NULL
primarily	NULL
activated	NULL
through	NULL
the	NULL
E2F	NULL
sites	NULL
during	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phase	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
pocket	NULL
proteins	NULL
complex	NULL
with	NULL
E2F	NULL
at	NULL
distinct	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Thus	NULL
,	NULL
p130-E2F	NULL
complexes	NULL
are	NULL
detected	NULL
exclusively	NULL
in	NULL
G	NULL
,	NULL
and	NULL
cells	NULL
exiting	NULL
G	NULL
,	NULL
,	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
pRB-E2F	NULL
complexes	NULL
exist	NULL
predominantly	NULL
in	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
,	NULL
whereas	NULL
complexes	NULL
containing	NULL
p107	NULL
are	NULL
detected	NULL
almost	NULL
throughout	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

The	NULL
pocket	NULL
proteins	NULL
are	NULL
phosphoproteins	NULL
,	NULL
and	NULL
their	NULL
expression	NULL
levels	NULL
and	NULL
phosphorylation	NULL
states	NULL
primarily	NULL
determine	NULL
their	NULL
interaction	NULL
with	NULL
E2F	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
29-33	NULL
)	NULL
.	NULL

pRB	NULL
is	NULL
hypo-	NULL
and/or	NULL
unphosphorylated	NULL
in	NULL
early	NULL
G	NULL
;	NULL
and	NULL
becomes	NULL
progressively	NULL
hyperphosphorylated	NULL
toward	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
.	NULL

The	NULL
consequence	NULL
of	NULL
pRB	NULL
hyperphosphorylation	NULL
is	NULL
the	NULL
release	NULL
of	NULL
``	NULL
free	NULL
``	NULL
E2F	NULL
,	NULL
which	NULL
activates	NULL
the	NULL
transcription	NULL
of	NULL
E2F-regulated	NULL
genes	NULL
(	NULL
34-36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
exceptions	NULL
to	NULL
this	NULL
general	NULL
concept	NULL
have	NULL
also	NULL
been	NULL
reported	NULL
,	NULL
as	NULL
some	NULL
pRB-E2F	NULL
complexes	NULL
persist	NULL
well	NULL
into	NULL
S	NULL
and	NULL
G	NULL
;	NULL
phases	NULL
(	NULL
37	NULL
)	NULL
.	NULL

In	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
;	NULL
,	NULL
p107	NULL
is	NULL
present	NULL
at	NULL
low	NULL
levels	NULL
in	NULL
a	NULL
hypophosphorylated	NULL
form	NULL
.	NULL

As	NULL
cells	NULL
progress	NULL
toward	NULL
late	NULL
G	NULL
,	NULL
,	NULL
the	NULL
level	NULL
of	NULL
p107	NULL
expressed	NULL
increases	NULL
,	NULL
and	NULL
the	NULL
majority	NULL
becomes	NULL
hyperphosphorylated	NULL
.	NULL

(	NULL
29	NULL
)	NULL
.	NULL

Hypophosphorylated	NULL
forms	NULL
of	NULL
p130	NULL
are	NULL
detected	NULL
primarily	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
;	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

In	NULL
p130	NULL
becomes	NULL
hyperphosphorylated	NULL
,	NULL
which	NULL
persists	NULL
for	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
82	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
p130	NULL
at	NULL
mid-G	NULL
,	NULL
is	NULL
believed	NULL
to	NULL
play	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
relieving	NULL
E2F-mediated	NULL
repression	NULL
of	NULL
G	NULL
,	NULL
/S	NULL
phase	NULL
genes	NULL
(	NULL
7	NULL
)	NULL
,	NULL
including	NULL
E2F1I	NULL
and	NULL
B-myb	NULL
.	NULL

However	NULL
,	NULL
p130	NULL
may	NULL
not	NULL
regulate	NULL
E2F	NULL
activity	NULL
in	NULL
continuously	NULL
cycling	NULL
cells	NULL
as	NULL
it	NULL
is	NULL
present	NULL
at	NULL
low	NULL
levels	NULL
and/or	NULL
in	NULL
a	NULL
hyperphosphorylated	NULL
state	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Increasing	NULL
evidence	NULL
has	NULL
shown	NULL
that	NULL
cyclins	NULL
and	NULL
their	NULL
dependent	NULL
kinases	NULL
(	NULL
cdks	NULL
)	NULL
associate	NULL
with	NULL
pocket	NULL
proteins	NULL
and	NULL
are	NULL
largely	NULL
responsible	NULL
for	NULL
their	NULL
phosphorylation	NULL
in	NULL
vivo	NULL
(	NULL
5	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Though	NULL
previous	NULL
mobility	NULL
shift	NULL
analyses	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
predominant	NULL
E2F	NULL
complex	NULL
in	NULL
S	NULL
phase	NULL
12009	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
12010	NULL
consists	NULL
of	NULL
p107	NULL
,	NULL
E2F4	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
cyclin	NULL
A	NULL
(	NULL
19-21	NULL
,	NULL
37	NULL
,	NULL
41	NULL
)	NULL
,	NULL
recent	NULL
in	NULL
vivo	NULL
footprinting	NULL
studies	NULL
of	NULL
the	NULL
B-myb	NULL
,	NULL
cyclin	NULL
A	NULL
,	NULL
and	NULL
ede2	NULL
promoters	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
corresponding	NULL
E2F	NULL
sites	NULL
are	NULL
only	NULL
engaged	NULL
by	NULL
transcription	NULL
factors	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
;	NULL
but	NULL
are	NULL
largely	NULL
unoccupied	NULL
in	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
(	NULL
42-44	NULL
)	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
discrepancy	NULL
is	NULL
not	NULL
yet	NULL
understood	NULL
,	NULL
and	NULL
further	NULL
information	NULL
is	NULL
required	NULL
on	NULL
the	NULL
molecular	NULL
mechanisms	NULL
regulating	NULL
the	NULL
occupancy	NULL
of	NULL
the	NULL
endogenous	NULL
E2F	NULL
binding	NULL
sites	NULL
that	NULL
can	NULL
account	NULL
for	NULL
these	NULL
in	NULL
vivo	NULL
protection	NULL
patterns	NULL
.	NULL

The	NULL
E2F	NULL
transcription	NULL
factor	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
the	NULL
retinoblastoma	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
orchestrates	NULL
the	NULL
orderly	NULL
expression	NULL
of	NULL
cell	NULL
cycle	NULL
regulatory	NULL
proteins	NULL
at	NULL
specific	NULL
points	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
and	NULL
thereby	NULL
controls	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

Hence	NULL
,	NULL
the	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
are	NULL
convergence	NULL
points	NULL
of	NULL
positive	NULL
and	NULL
negative	NULL
proliferative	NULL
signals	NULL
.	NULL

Although	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
overexpression	NULL
of	NULL
E2F	NULL
activity	NULL
can	NULL
drive	NULL
cell	NULL
lines	NULL
from	NULL
G	NULL
,	NULL
(	NULL
quiescence	NULL
)	NULL
into	NULL
S	NULL
(	NULL
DNA	NULL
synthesis	NULL
)	NULL
phase	NULL
,	NULL
the	NULL
modulation	NULL
of	NULL
E2F	NULL
activity	NULL
that	NULL
accompanies	NULL
this	NULL
cell	NULL
cycle	NULL
phase	NULL
transition	NULL
in	NULL
primary	NULL
cells	NULL
under	NULL
normal	NULL
physiological	NULL
conditions	NULL
is	NULL
not	NULL
fully	NULL
defined	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
little	NULL
information	NULL
is	NULL
available	NULL
for	NULL
the	NULL
regulation	NULL
and	NULL
roles	NULL
of	NULL
the	NULL
DP	NULL
family	NULL
of	NULL
proteins	NULL
during	NULL
this	NULL
G	NULL
,	NULL
to	NULL
S	NULL
transition	NULL
,	NULL
despite	NULL
the	NULL
wealth	NULL
of	NULL
knowledge	NULL
relating	NULL
to	NULL
the	NULL
E2F	NULL
family	NULL
proteins	NULL
.	NULL

Moreover	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
roles	NULL
of	NULL
the	NULL
E2F	NULL
and	NULL
pRB	NULL
families	NULL
of	NULL
proteins	NULL
during	NULL
B-lymphocyte	NULL
activation	NULL
.	NULL

The	NULL
present	NULL
report	NULL
describes	NULL
the	NULL
modulation	NULL
of	NULL
E2F	NULL
complexes	NULL
during	NULL
human	NULL
B-lymphocyte	NULL
activation	NULL
through	NULL
stimulation	NULL
by	NULL
PMA*	NULL
'	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
and	NULL
explores	NULL
the	NULL
molecular	NULL
mechanisms	NULL
involved	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Isolation	NULL
of	NULL
Human	NULL
Primary	NULL
B-lymphocytes-Platelet	NULL
depleted	NULL
buffy	NULL
coats	NULL
obtained	NULL
from	NULL
the	NULL
National	NULL
Blood	NULL
Transfusion	NULL
Service	NULL
were	NULL
pooled	NULL
,	NULL
and	NULL
the	NULL
mononuclear	NULL
lymphocytes	NULL
were	NULL
enriched	NULL
using	NULL
Ficoll-Pagque	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
gradient	NULL
centrifugation	NULL
for	NULL
20	NULL
min	NULL
at	NULL
800	NULL
x	NULL
g.	NULL
The	NULL
B-lymphocytes	NULL
were	NULL
isolated	NULL
by	NULL
positive	NULL
selection	NULL
using	NULL
CD19-coupled	NULL
Dynabeads	NULL
(	NULL
M-450	NULL
pan-B	NULL
,	NULL
Dynall	NULL
)	NULL
.	NULL

The	NULL
B-lymphocytes	NULL
captured	NULL
by	NULL
the	NULL
magnetic	NULL
beads	NULL
were	NULL
then	NULL
released	NULL
using	NULL
De-tachabeads	NULL
(	NULL
Dynall	NULL
)	NULL
.	NULL

As	NULL
the	NULL
control	NULL
,	NULL
small	NULL
dense	NULL
B-lymphocytes	NULL
were	NULL
also	NULL
isolated	NULL
by	NULL
flow	NULL
cytometric	NULL
sorting	NULL
from	NULL
human	NULL
tonsils	NULL
,	NULL
as	NULL
described	NULL
(	NULL
45	NULL
)	NULL
.	NULL

The	NULL
freshly	NULL
purified	NULL
B-lymphocytes	NULL
were	NULL
seeded	NULL
at	NULL
10°	NULL
cells/ml	NULL
in	NULL
culture	NULL
medium	NULL
containing	NULL
15	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
in	NULL
RPMI	NULL
and	NULL
incubated	NULL
for	NULL
at	NULL
least	NULL
86	NULL
h	NULL
at	NULL
37°C	NULL
before	NULL
stimulation	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
PMA	NULL
at	NULL
30	NULL
ug/ml	NULL
.	NULL

Purity	NULL
of	NULL
B-lymphocytes	NULL
was	NULL
assessed	NULL
by	NULL
staining	NULL
with	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
anti-human	NULL
B	NULL
cell	NULL
(	NULL
CD20	NULL
)	NULL
antibodies	NULL
(	NULL
DAKO	NULL
)	NULL
and	NULL
assayed	NULL
using	NULL
flow	NULL
cytometry	NULL
.	NULL

Flow	NULL
Cytometric	NULL
Analyses-Cell	NULL
cycle	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
propidium	NULL
iodide	NULL
and	NULL
FITC	NULL
staining	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
with	NULL
PBS	NULL
before	NULL
fixing	NULL
in	NULL
20	NULL
%	NULL
PBS	NULL
and	NULL
80	NULL
%	NULL
ethanol	NULL
.	NULL

The	NULL
fixed	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
PBS	NULL
and	NULL
incubated	NULL
with	NULL
DNase	NULL
free-RNase	NULL
(	NULL
0.5	NULL
mg/m	NULL
!	NULL
)	NULL

,	NULL
propidium	NULL
iodide	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
,	NULL
and	NULL
FITC	NULL
(	NULL
0.05	NULL
ug/m1	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
before	NULL
analysis	NULL
using	NULL
a	NULL
EPICS-Elite	NULL
flow	NULL
cytometer	NULL
(	NULL
Coulter	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

For	NULL
anti-CD20	NULL
staining	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
ug/ml	NULL
FITC-conjugated	NULL
anti-human	NULL
CD20	NULL
antibody	NULL
(	NULL
Dako	NULL
A/S	NULL
,	NULL
Denmark	NULL
)	NULL
in	NULL
PBS	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
before	NULL
fixing	NULL
with	NULL
ethanol/PBS	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
and	NULL
Supershift	NULL
Analyses	NULL
of	NULL
E2F	NULL
DNA	NULL
Binding	NULL
Complexes-Whole	NULL
cell	NULL
extracts	NULL
from	NULL
human	NULL
B-lymphocytes	NULL
were	NULL
prepared	NULL
as	NULL
detailed	NULL
previously	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Protein	NULL
yield	NULL
was	NULL
quantified	NULL
by	NULL
Bradford	NULL
analysis	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

E2F	NULL
gel	NULL
retardation	NULL
assays	NULL
were	NULL
performed	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
,	NULL
using	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
(	NULL
5'-GATCTAGTTTTCGCGCTTAAATTTGA	NULL
)	NULL
containing	NULL
the	NULL
distal	NULL
E2F	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
adenovirus	NULL
type	NULL
5	NULL
E2a	NULL
promoter	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Twenty	NULL
ug	NULL
of	NULL
whole	NULL
cell	NULL
extract	NULL
was	NULL
incubated	NULL
with	NULL
1-2	NULL
ng	NULL
of	NULL
*°P-labeled	NULL
oligonucleotide	NULL
probe	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
ug	NULL
of	NULL
sonicated	NULL
salmon	NULL
sperm	NULL
DNA	NULL
and	NULL
200	NULL
ng	NULL
of	NULL
a	NULL
comparable	NULL
unlabeled	NULL
double-stranded	NULL
oligonucleotide	NULL
with	NULL
mutated	NULL
E2F	NULL
site	NULL
(	NULL
5-GATCTAGTTTTCGATAT-TAAATTTGA	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
at	NULL
80°C	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
electrophoresed	NULL
on	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.33	NULL
%	NULL
Tris-buffered	NULL
EDTA	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
then	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
x-ray	NULL
films	NULL
.	NULL

Supershift	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
adding	NULL
1	NULL
ul	NULL
of	NULL
concentrated	NULL
antibodies	NULL
.	NULL

Rabbit	NULL
anti-pRB2/p1830	NULL
and	NULL
anti-cyclin	NULL
A	NULL
antisera	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
A.	NULL
Giordano	NULL
and	NULL
Dr.	NULL
J.	NULL
Pines	NULL
,	NULL
respectively	NULL
.	NULL

Anti-pRB	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
21C9	NULL
(	NULL
58	NULL
)	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
Sybille	NULL
Mittnacht	NULL
.	NULL

Anti-DP1	NULL
,	NULL
-E2F1	NULL
,	NULL
-E2F4	NULL
rabbit	NULL
antisera	NULL
were	NULL
raised	NULL
against	NULL
peptides	NULL
corresponding	NULL
to	NULL
unique	NULL
carboxyl-terminal	NULL
regions	NULL
of	NULL
the	NULL
respective	NULL
human	NULL
proteins	NULL
and	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
49	NULL
)	NULL
.	NULL

The	NULL
anti-DP2	NULL
polyclonal	NULL
antibodies	NULL
were	NULL
raised	NULL
against	NULL
peptides	NULL
corresponding	NULL
to	NULL
unique	NULL
regions	NULL
at	NULL
the	NULL
carboxyl-terminal	NULL
end	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Anti-E2F2	NULL
(	NULL
L-20	NULL
)	NULL
,	NULL
anti-E2F3	NULL
(	NULL
N-20	NULL
)	NULL
,	NULL
and	NULL
anti-E2F5	NULL
(	NULL
E19	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

Western	NULL
Blot	NULL
Analysis	NULL
and	NULL
Antibodies-Western	NULL
blot	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
B-lymphocytes	NULL
by	NULL
lysing	NULL
cells	NULL
with	NULL
4	NULL
times	NULL
the	NULL
packed	NULL
cell	NULL
volume	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxy-cholate	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
50	NULL
mM	NULL
NaF	NULL
,	NULL
5	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
)	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Fifty	NULL
ug	NULL
of	NULL
lysate	NULL
was	NULL
separated	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
,	NULL
and	NULL
recognized	NULL
by	NULL
specific	NULL
antibodies	NULL
.	NULL

The	NULL
antibodies	NULL
were	NULL
detected	NULL
using	NULL
horseradish	NULL
peroxidase-linked	NULL
goat	NULL
anti-mouse	NULL
or	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
Dako	NULL
)	NULL
and	NULL
visualized	NULL
by	NULL
the	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
detection	NULL
system	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
anti-DP1	NULL
and	NULL
DP2	NULL
monoclonal	NULL
antibodies	NULL
were	NULL
raised	NULL
against	NULL
s6-His-tagged	NULL
(	NULL
Qiagen	NULL
)	NULL
peptides	NULL
corresponding	NULL
to	NULL
unique	NULL
amino-terminal	NULL
regions	NULL
of	NULL
the	NULL
corresponding	NULL
human	NULL
proteins	NULL
.	NULL

The	NULL
antibodies	NULL
against	NULL
E2F1	NULL
(	NULL
KH95	NULL
)	NULL
,	NULL
E2F2	NULL
(	NULL
L-20	NULL
)	NULL
,	NULL
E2F3	NULL
(	NULL
N-20	NULL
)	NULL
,	NULL
E2F4	NULL
(	NULL
C-20	NULL
)	NULL
,	NULL
E2F5	NULL
(	NULL
MHS5	NULL
)	NULL
,	NULL
pRB	NULL
(	NULL
C-15	NULL
)	NULL
,	NULL
p107	NULL
(	NULL
C-18	NULL
)	NULL
,	NULL
and	NULL
p1830	NULL
(	NULL
C-20	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

The	NULL
monoclonal	NULL
antibody	NULL
against	NULL
human	NULL
c-MYC	NULL
was	NULL
prepared	NULL
from	NULL
supernatant	NULL
of	NULL
the	NULL
hybri-doma	NULL
9E10	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Phosphatase	NULL
Treatment	NULL
of	NULL
Cell	NULL
Extracts-Dephosphorylation	NULL
of	NULL
cell	NULL
extracts	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
whole	NULL
cell	NULL
extracts	NULL
with	NULL
500	NULL
units	NULL
of	NULL
A	NULL
protein	NULL
phosphatase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
at	NULL
30	NULL
°C	NULL
for	NULL
1	NULL
h	NULL
as	NULL
detailed	NULL
before	NULL
(	NULL
55	NULL
)	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
stopped	NULL
by	NULL
boiling	NULL
with	NULL
SDS	NULL
sample	NULL
buffer	NULL
,	NULL
separated	NULL
on	NULL
SDS-polyacrylamide	NULL
gels	NULL
,	NULL
and	NULL
Western-blotted	NULL
with	NULL
the	NULL
appropriate	NULL
antibodies	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
anti-E2F4	NULL
polyclonal	NULL
antibodies	NULL
also	NULL
recognized	NULL
an	NULL
unspecific	NULL
band	NULL
(	NULL
indicated	NULL
by	NULL
asferisk	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
in	NULL
the	NULL
whole	NULL
cell	NULL
ex-tracts	NULL
,	NULL
which	NULL
was	NULL
not	NULL
detected	NULL
previously	NULL
in	NULL
the	NULL
Western	NULL
blot	NULL
lysate	NULL
.	NULL

DNA	NULL
Binding	NULL
Assay-DNA	NULL
binding	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
88	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
collected	NULL
and	NULL
lysed	NULL
on	NULL
ice	NULL
for	NULL
10	NULL
min	NULL
in	NULL
lysis	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
Nonidet	NULL
P-40	NULL
supplemented	NULL
with	NULL
protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
as	NULL
detailed	NULL
by	NULL
Thomas	NULL
(	NULL
60	NULL
)	NULL
.	NULL

After	NULL
clearing	NULL
by	NULL
centrifugation	NULL
,	NULL
the	NULL
nuclear	NULL
pellet	NULL
was	NULL
lysed	NULL
further	NULL
with	NULL
1/10	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
containing	NULL
450	NULL
mM	NULL
NaCl	NULL
.	NULL

Both	NULL
the	NULL
high	NULL
salt	NULL
and	NULL
low	NULL
salt	NULL
supernatants	NULL
were	NULL
combined	NULL
and	NULL
then	NULL
incubated	NULL
at	NULL
4	NULL
°C	NULL
for	NULL
1	NULL
h	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
mutant	NULL
double-stranded	NULL
5'-biotinylated	NULL
E2F	NULL
oligonucleotide	NULL
(	NULL
as	NULL
described	NULL
for	NULL
mobility	NULL
shift	NULL
assay	NULL
)	NULL
and	NULL
20	NULL
ul	NULL
of	NULL
avidin-coupled	NULL
methacrylate	NULL
matrix	NULL
(	NULL
Softlink	NULL
Avidin	NULL
,	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
then	NULL
incubated	NULL
similarly	NULL
with	NULL
the	NULL
wild-type	NULL
E2F	NULL
oligonucleotide	NULL
and	NULL
avidin	NULL
beads	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
the	NULL
beads	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
low	NULL
salt	NULL
lysis	NULL
buffer	NULL
and	NULL
then	NULL
boiled	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
before	NULL
examination	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

RESULTS	NULL
Cell	NULL
Cycle	NULL
Analysis	NULL
of	NULL
Human	NULL
Primary	NULL
B-lymphocytes	NULL
after	NULL
Stimulation	NULL
with	NULL
PMA-Human	NULL
B-lymphocytes	NULL
were	NULL
purified	NULL
from	NULL
platelet-depleted	NULL
buffy	NULL
coats	NULL
by	NULL
positive	NULL
selection	NULL
using	NULL
CD19-conjugated	NULL
immunomagnetic	NULL
beads	NULL
after	NULL
preliminary	NULL
enrichment	NULL
over	NULL
Ficoll	NULL
density	NULL
gradients	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
human	NULL
B-lymphocytes	NULL
isolated	NULL
by	NULL
this	NULL
procedure	NULL
was	NULL
routinely	NULL
more	NULL
than	NULL
95	NULL
%	NULL
,	NULL
as	NULL
verified	NULL
by	NULL
staining	NULL
using	NULL
fluorochrome-conju-gated	NULL
CD20	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

The	NULL
purified	NULL
human	NULL
B-lymphocytes	NULL
were	NULL
then	NULL
stimulated	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
using	NULL
PMA	NULL
,	NULL
and	NULL
their	NULL
cell	NULL
cycle	NULL
status	NULL
was	NULL
monitored	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
both	NULL
DNA	NULL
and	NULL
protein	NULL
content	NULL
,	NULL
gauged	NULL
by	NULL
the	NULL
levels	NULL
of	NULL
propidium	NULL
iodide	NULL
and	NULL
FITC	NULL
staining	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Untreated	NULL
B-lymphocytes	NULL
had	NULL
a	NULL
2N	NULL
DNA	NULL
and	NULL
a	NULL
low	NULL
protein	NULL
content	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
unstimulated	NULL
B-lymphocytes	NULL
were	NULL
in	NULL
G	NULL
,	NULL
.	NULL

Upon	NULL
PMA	NULL
stimulation	NULL
,	NULL
the	NULL
first	NULL
sign	NULL
of	NULL
increased	NULL
cellular	NULL
protein	NULL
content	NULL
(	NULL
FITC	NULL
staining	NULL
)	NULL
was	NULL
observed	NULL
at	NULL
12	NULL
h	NULL
,	NULL
indicating	NULL
that	NULL
cells	NULL
were	NULL
beginning	NULL
to	NULL
enter	NULL
early	NULL
G	NULL
,	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
cells	NULL
traversed	NULL
the	NULL
G/G	NULL
,	NULL
boundary	NULL
between	NULL
24	NULL
and	NULL
36	NULL
h.	NULL
A	NULL
small	NULL
population	NULL
of	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
8	NULL
8	NULL
1.1	NULL
%	NULL
98.8	NULL
%	NULL
8	NULL
8	NULL
28	NULL
£8	NULL
8¢	NULL
8¢	NULL
8	NULL
&	NULL
B	NULL
o	NULL
wh	NULL
oad	NULL
)	NULL
ast	NULL
ao	NULL
as	NULL
wh	NULL
ae	NULL
|	NULL
ant	NULL
aot	NULL
ant	NULL
FitHoight	NULL
Fut-Hoignt	NULL
U	NULL
42h	NULL
Protein	NULL
Content	NULL
DNA	NULL
Content	NULL
Oh	NULL
|	NULL
12h	NULL
|	NULL
24h	NULL
|	NULL
30h	NULL
|	NULL
36h	NULL
|	NULL
42h	NULL
|	NULL
48h	NULL
|	NULL
60h	NULL
|	NULL
72h	NULL
GO	NULL
85.7	NULL
|	NULL
80.5	NULL
|	NULL
52.9	NULL
|	NULL
34.8	NULL
|	NULL
16.2	NULL
|	NULL
11.9	NULL
|	NULL
8.3	NULL
|	NULL
4.0	NULL
|	NULL
10.1	NULL
G1	NULL
5.0	NULL
|	NULL
10.1	NULL
|	NULL
40.9	NULL
|	NULL
59.4	NULL
|	NULL
78.7	NULL
|	NULL
80.9	NULL
|	NULL
88.6	NULL
|	NULL
79.5	NULL
|	NULL
72.0	NULL
S	NULL
2.2	NULL
|	NULL
2.0	NULL
1.5	NULL
1.8	NULL
1.1	NULL
2.4	NULL
1.5	NULL
|	NULL
10.2	NULL
|	NULL
11.1	NULL
G2/M	NULL
7.1	NULL
7.5	NULL
4.7	NULL
3.9	NULL
|	NULL
4.0	NULL
|	NULL
4.7	NULL
1.7	NULL
6.4	NULL
|	NULL
6.9	NULL
12011	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Flow	NULL
cytometric	NULL
analyses	NULL
of	NULL
primary	NULL
B-lymphocytes	NULL
isolated	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
.	NULL

A	NULL
,	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
CD20	NULL
expression	NULL
in	NULL
B-lymphocytes	NULL
.	NULL

B-lymphocytes	NULL
isolated	NULL
using	NULL
anti-CD19	NULL
magnetic	NULL
beads	NULL
were	NULL
stained	NULL
with	NULL
fluorescein	NULL
FITC-conjugated	NULL
anti-CD20	NULL
antibodies	NULL
before	NULL
(	NULL
lef	NULL
?	NULL
)	NULL

and	NULL
after	NULL
(	NULL
right	NULL
)	NULL
selection	NULL
with	NULL
CD19	NULL
magnetic	NULL
beads	NULL
.	NULL

B	NULL
,	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
cell	NULL
cycle	NULL
phases	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
and	NULL
collected	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

Total	NULL
protein	NULL
level	NULL
was	NULL
measured	NULL
by	NULL
FITC	NULL
staining	NULL
,	NULL
and	NULL
DNA	NULL
content	NULL
was	NULL
measured	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
.	NULL

The	NULL
percentages	NULL
of	NULL
cells	NULL
in	NULL
various	NULL
cell	NULL
cycle	NULL
phases	NULL
(	NULL
G	NULL
,	NULL
,	NULL
G	NULL
,	NULL
,	NULL
S	NULL
,	NULL
and	NULL
G	NULL
,	NULL
/M	NULL
)	NULL
at	NULL
different	NULL
times	NULL
after	NULL
PMA	NULL
stimulation	NULL
are	NULL
shown	NULL
.	NULL

PMA-stimulated	NULL
cells	NULL
began	NULL
to	NULL
enter	NULL
S	NULL
phase	NULL
(	NULL
DNA	NULL
synthesis	NULL
)	NULL
at	NULL
60	NULL
h	NULL
,	NULL
which	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
their	NULL
DNA	NULL
content	NULL
.	NULL

It	NULL
is	NULL
also	NULL
notable	NULL
that	NULL
with	NULL
PMA	NULL
stimulation	NULL
alone	NULL
,	NULL
the	NULL
majority	NULL
of	NULL
cells	NULL
remained	NULL
in	NULL
G/G	NULL
,	NULL
after	NULL
72	NULL
h.	NULL
The	NULL
relatively	NULL
long	NULL
G4	NULL
made	NULL
this	NULL
cell	NULL
system	NULL
ideal	NULL
for	NULL
investigating	NULL
the	NULL
early	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Changes	NULL
in	NULL
E2F	NULL
DNA	NULL
Binding	NULL
Activity	NULL
in	NULL
Human	NULL
Primary	NULL
B-lymphocytes	NULL
after	NULL
Stimulation	NULL
with	NULL
PMA-To	NULL
characterize	NULL
the	NULL
functional	NULL
E2F	NULL
complexes	NULL
in	NULL
human	NULL
B-lymphocytes	NULL
,	NULL
mobility	NULL
shift	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
extracts	NULL
derived	NULL
from	NULL
PMA-stimulated	NULL
cells	NULL
.	NULL

The	NULL
mobility-shift	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
identified	NULL
at	NULL
least	NULL
five	NULL
species	NULL
of	NULL
DNA	NULL
binding	NULL
complexes	NULL
containing	NULL
E2F	NULL
(	NULL
complexes	NULL
A	NULL
to	NULL
£	NULL
)	NULL
by	NULL
virtue	NULL
of	NULL
the	NULL
difference	NULL
in	NULL
their	NULL
mobility	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
two	NULL
are	NULL
free	NULL
E2F	NULL
's	NULL
(	NULL
complexes	NULL
D	NULL
and	NULL
E	NULL
)	NULL
,	NULL
and	NULL
the	NULL
other	NULL
three	NULL
are	NULL
complexed	NULL
E2Fs	NULL
(	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
)	NULL
,	NULL
shown	NULL
previously	NULL
also	NULL
to	NULL
contain	NULL
the	NULL
pRB-related	NULL
pocket	NULL
proteins	NULL
.	NULL

As	NULL
we	NULL
have	NULL
shown	NULL
previously	NULL
(	NULL
48	NULL
)	NULL
,	NULL
only	NULL
one	NULL
predominant	NULL
species	NULL
of	NULL
E2F	NULL
complex	NULL
(	NULL
complex	NULL
B	NULL
)	NULL
was	NULL
detected	NULL
in	NULL
unstimulated	NULL
human	NULL
B-lymphocytes	NULL
.	NULL

Upon	NULL
PMA	NULL
stimulation	NULL
,	NULL
the	NULL
level	NULL
of	NULL
this	NULL
complexed	NULL
E2F	NULL
(	NULL
complex	NULL
B	NULL
)	NULL
increased	NULL
,	NULL
reaching	NULL
a	NULL
peak	NULL
at	NULL
30	NULL
h.	NULL
However	NULL
,	NULL
as	NULL
the	NULL
cells	NULL
progressed	NULL
toward	NULL
S	NULL
phase	NULL
,	NULL
this	NULL
E2F	NULL
complex	NULL
declined	NULL
gradually	NULL
and	NULL
was	NULL
eventually	NULL
replaced	NULL
by	NULL
two	NULL
other	NULL
complexed	NULL
E2Fs	NULL
(	NULL
complexes	NULL
A	NULL
and	NULL
C	NULL
)	NULL
and	NULL
two	NULL
free	NULL
E2F	NULL
species	NULL
(	NULL
complexes	NULL
D	NULL
and	NULL
E	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
components	NULL
of	NULL
these	NULL
E2F	NULL
complexes	NULL
,	NULL
we	NULL
per	NULL
formed	NULL
antibody	NULL
supershift	NULL
experiments	NULL
on	NULL
extracts	NULL
corresponding	NULL
to	NULL
B-lymphocytes	NULL
at	NULL
Gy	NULL
,	NULL
G	NULL
;	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
(	NULL
0	NULL
h	NULL
)	NULL
,	NULL
the	NULL
anti-pRB	NULL
antibody	NULL
supershifted	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
EZ2F	NULL
complex	NULL
(	NULL
complex	NULL
B	NULL
)	NULL
found	NULL
in	NULL
the	NULL
G	NULL
,	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
whereas	NULL
the	NULL
anti-p130	NULL
antibody	NULL
shifted	NULL
less	NULL
than	NULL
50	NULL
%	NULL
of	NULL
this	NULL
G	NULL
,	NULL
complex	NULL
,	NULL
and	NULL
the	NULL
anti-p107	NULL
failed	NULL
to	NULL
shift	NULL
this	NULL
complex	NULL
at	NULL
all	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-cyclin	NULL
A	NULL
antibody	NULL
produced	NULL
an	NULL
unspecific	NULL
band	NULL
but	NULL
failed	NULL
to	NULL
disrupt	NULL
the	NULL
G	NULL
,	NULL
complex	NULL
,	NULL
indicating	NULL
that	NULL
cyclin	NULL
A	NULL
is	NULL
not	NULL
present	NULL
in	NULL
the	NULL
Gy	NULL
E2F	NULL
complex	NULL
in	NULL
B-lymphocytes	NULL
.	NULL

It	NULL
is	NULL
notable	NULL
that	NULL
the	NULL
anti-cyclin	NULL
A	NULL
used	NULL
here	NULL
does	NULL
not	NULL
supershift	NULL
E2F	NULL
complexes	NULL
but	NULL
disrupts	NULL
E2F	NULL
complexes	NULL
containing	NULL
cyclin	NULL
A	NULL
(	NULL
49	NULL
)	NULL
.	NULL

The	NULL
G	NULL
,	NULL
complex	NULL
could	NULL
also	NULL
be	NULL
supershifted	NULL
by	NULL
the	NULL
anti-E2F4	NULL
antibody	NULL
but	NULL
not	NULL
antibodies	NULL
against	NULL
E2F1	NULL
,	NULL
-2	NULL
,	NULL
-3	NULL
.	NULL

Antibodies	NULL
raised	NULL
against	NULL
DP1	NULL
could	NULL
again	NULL
shift	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
complex	NULL
,	NULL
and	NULL
the	NULL
remaining	NULL
E2F	NULL
complex	NULL
could	NULL
be	NULL
shifted	NULL
by	NULL
different	NULL
anti-DP2	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
though	NULL
DPI	NULL
is	NULL
the	NULL
predominant	NULL
DP	NULL
protein	NULL
present	NULL
in	NULL
these	NULL
complexes	NULL
,	NULL
a	NULL
low	NULL
level	NULL
of	NULL
DP2	NULL
is	NULL
also	NULL
complexed	NULL
with	NULL
E2F4	NULL
and	NULL
pRB	NULL
or	NULL
p130	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
propose	NULL
that	NULL
the	NULL
predominant	NULL
E2F	NULL
complex	NULL
(	NULL
B	NULL
)	NULL
present	NULL
in	NULL
unstimulated	NULL
,	NULL
quiescent	NULL
B-lymphocytes	NULL
largely	NULL
contains	NULL
E2F4	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
pRB	NULL
or	NULL
p130	NULL
.	NULL

It	NULL
is	NULL
also	NULL
notable	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
G	NULL
,	NULL
,	NULL
complex	NULL
contains	NULL
pRB	NULL
instead	NULL
of	NULL
p130	NULL
complexing	NULL
with	NULL
E2F4	NULL
and	NULL
DPL	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
what	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
present	NULL
in	NULL
quiescent	NULL
cells	NULL
of	NULL
other	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
12012	NULL
A	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
0	NULL
12	NULL
24	NULL
30	NULL
36	NULL
42	NULL
48	NULL
60	NULL
72	NULL
Lliigﬂi	NULL
a	NULL
S	NULL
#	NULL
$	NULL
2	NULL
I4	NULL
24	NULL
b	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
C	NULL
TJ	NULL
~	NULL
~	NULL
a	NULL
1	NULL
DP1	NULL
,	NULL
DP1+DP2a	NULL
&	NULL
1	NULL
DP1+DP2c	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
analysis	NULL
of	NULL
E2F	NULL
DNA	NULL
binding	NULL
complexes	NULL
after	NULL
PMA	NULL
stimulation	NULL
.	NULL

A	NULL
,	NULL
whole	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
human	NULL
B-lymphocytes	NULL
at	NULL
times	NULL
indicated	NULL
after	NULL
PMA	NULL
stimulation	NULL
.	NULL

The	NULL
extracts	NULL
were	NULL
then	NULL
used	NULL
for	NULL
gel	NULL
mobility	NULL
shift	NULL
experiments	NULL
with	NULL
a	NULL
``	NULL
°P-labeled	NULL
E2ZF	NULL
oligonucleotide	NULL
as	NULL
probe	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
different	NULL
EZF	NULL
complexes	NULL
are	NULL
labeled	NULL
A	NULL
to	NULL
E.	NULL
B	NULL
,	NULL
antibody	NULL
supershift	NULL
analysis	NULL
of	NULL
components	NULL
of	NULL
E2F	NULL
complexes	NULL
at	NULL
different	NULL
cell	NULL
cycle	NULL
stages	NULL
.	NULL

Supershifts	NULL
were	NULL
performed	NULL
using	NULL
specific	NULL
antibodies	NULL
against	NULL
pRB	NULL
,	NULL
p107	NULL
,	NULL
p130	NULL
,	NULL
cyclin	NULL
A	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
E2F1-5	NULL
as	NULL
indicated	NULL
on	NULL
whole	NULL
cell	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
at	NULL
0	NULL
,	NULL
24	NULL
,	NULL
42	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
h	NULL
after	NULL
PMA	NULL
stimulation	NULL
.	NULL

Band	NULL
A	NULL
in	NULL
panel	NULL
A	NULL
consists	NULL
mainly	NULL
of	NULL
p107-cyclin	NULL
A-E2F4-DP1	NULL
,	NULL
band	NULL
B	NULL
contains	NULL
primarily	NULL
pRB	NULL
and	NULL
p180-E2F4-DP1	NULL
,	NULL
band	NULL
C	NULL
contains	NULL
pRB-E2F1-3-DP1	NULL
,	NULL
band	NULL
D	NULL
contains	NULL
E2F4-DP1	NULL
,	NULL
and	NULL
band	NULL
E	NULL
contains	NULL
E2F1-3	NULL
and	NULL
5-DP1	NULL
.	NULL

C	NULL
,	NULL
supershift	NULL
analysis	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
DP2	NULL
in	NULL
E2F	NULL
complexes	NULL
.	NULL

The	NULL
whole	NULL
cell	NULL
extract	NULL
from	NULL
unstimulated	NULL
B-lymphocytes	NULL
was	NULL
supershifted	NULL
with	NULL
anti-DP2	NULL
polyclonal	NULL
antibodies	NULL
(	NULL
DP2a	NULL
,	NULL
-b	NULL
,	NULL
and	NULL
-c	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-DP1	NULL
antibody	NULL
.	NULL

primary	NULL
cell	NULL
types	NULL
.	NULL

For	NULL
example	NULL
,	NULL
in	NULL
quiescent	NULL
serum-starved	NULL
mouse	NULL
fibroblasts	NULL
and	NULL
in	NULL
resting	NULL
human	NULL
primary	NULL
T	NULL
lymphocytes	NULL
and	NULL
CD34	NULL
*	NULL
cells	NULL
,	NULL
the	NULL
major	NULL
E2F	NULL
complex	NULL
consists	NULL
of	NULL
E2F4	NULL
and	NULL
DP1	NULL
complexed	NULL
with	NULL
p130	NULL
(	NULL
9	NULL
,	NULL
27	NULL
,	NULL
41	NULL
,	NULL
48	NULL
,	NULL
50	NULL
)	NULL
.	NULL

As	NULL
the	NULL
B-lymphocytes	NULL
progressed	NULL
into	NULL
early	NULL
G	NULL
,	NULL
(	NULL
24	NULL
h	NULL
)	NULL
,	NULL
there	NULL
was	NULL
a	NULL
general	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
this	NULL
pRB-	NULL
or	NULL
p130	NULL
containing	NULL
E2F	NULL
complex	NULL
(	NULL
complex	NULL
B	NULL
)	NULL
,	NULL
although	NULL
the	NULL
components	NULL
of	NULL
this	NULL
complex	NULL
remained	NULL
unchanged	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
supershift	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
at	NULL
this	NULL
time	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
free	NULL
E2F	NULL
started	NULL
to	NULL
accumulate	NULL
.	NULL

The	NULL
slower	NULL
migrating	NULL
free	NULL
E2F	NULL
(	NULL
complex	NULL
D	NULL
)	NULL
can	NULL
be	NULL
supershifted	NULL
by	NULL
anti-E2F4	NULL
,	NULL
whereas	NULL
the	NULL
higher	NULL
mobility	NULL
free	NULL
E2F	NULL
(	NULL
complex	NULL
E	NULL
)	NULL
can	NULL
only	NULL
be	NULL
shifted	NULL
by	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
0	NULL
12	NULL
24	NULL
30	NULL
36	NULL
42	NULL
48	NULL
60	NULL
72	NULL
0	NULL
DP1C	NULL
FFA	NULL
E2F1L	NULL
-==	NULL
E2F3L	NULL
mae	NULL
a	NULL
c-Myc	NULL
__	NULL
wm	NULL
oe	NULL
0	NULL
12	NULL
24	NULL
30	NULL
42	NULL
48	NULL
60	NULL
72	NULL
E	NULL
wee	NULL
~4pe	NULL
DPC	NULL
68	NULL
wee	NULL
me	NULL
m	NULL
ae	NULL
in	NULL
am	NULL
C	NULL
®	NULL
se	NULL
aes	NULL
aan	NULL
qu	NULL
»	NULL
ah	NULL
«	NULL
#	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
E2F	NULL
,	NULL
DP	NULL
,	NULL
and	NULL
c-MYC	NULL
protein	NULL
expression	NULL
after	NULL
PMA	NULL
stimulation	NULL
.	NULL

Western	NULL
blot	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
at	NULL
times	NULL
indicated	NULL
after	NULL
PMA	NULL
treatment	NULL
were	NULL
separated	NULL
on	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
and	NULL
immunoblotted	NULL
with	NULL
antibodies	NULL
against	NULL
E2F1-5	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
DP2	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
monoclonal	NULL
antibody	NULL
against	NULL
human	NULL
c-MYC	NULL
,	NULL
9610	NULL
(	NULL
59	NULL
)	NULL
.	NULL

antibodies	NULL
to	NULL
E2F5	NULL
but	NULL
not	NULL
other	NULL
E2Fs	NULL
.	NULL

In	NULL
late	NULL
G	NULL
,	NULL
/S	NULL
phase	NULL
(	NULL
48	NULL
h	NULL
,	NULL
72	NULL
h	NULL
)	NULL
,	NULL
the	NULL
complexes	NULL
containing	NULL
pRB	NULL
and	NULL
p130	NULL
disappeared	NULL
and	NULL
were	NULL
replaced	NULL
by	NULL
at	NULL
least	NULL
four	NULL
different	NULL
E2F	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Subsequent	NULL
supershift	NULL
analyses	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
showed	NULL
that	NULL
the	NULL
slowest	NULL
migrating	NULL
E2F	NULL
complex	NULL
(	NULL
complex	NULL
A	NULL
)	NULL
contains	NULL
predominantly	NULL
p107	NULL
,	NULL
cyclin	NULL
A	NULL
,	NULL
E2F4	NULL
,	NULL
and	NULL
DP1	NULL
,	NULL
the	NULL
faster	NULL
complexed	NULL
E2F	NULL
(	NULL
complex	NULL
C	NULL
)	NULL
consists	NULL
of	NULL
pRB	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
E2F1	NULL
,	NULL
-2	NULL
,	NULL
-3	NULL
,	NULL
or	NULL
-4	NULL
,	NULL
the	NULL
slower	NULL
of	NULL
the	NULL
two	NULL
free	NULL
E2F	NULL
(	NULL
complex	NULL
D	NULL
)	NULL
is	NULL
composed	NULL
of	NULL
DP1	NULL
and	NULL
E2F4	NULL
,	NULL
and	NULL
finally	NULL
,	NULL
the	NULL
fastest	NULL
migrating	NULL
complex	NULL
(	NULL
complex	NULL
E	NULL
)	NULL
is	NULL
made	NULL
up	NULL
mainly	NULL
of	NULL
DP1	NULL
complexed	NULL
either	NULL
with	NULL
E2F1	NULL
,	NULL
-2	NULL
,	NULL
-3	NULL
,	NULL
or	NULL
-5	NULL
.	NULL

Although	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
E2F1	NULL
,	NULL
-2	NULL
,	NULL
and	NULL
-3	NULL
interact	NULL
specifically	NULL
with	NULL
pRB	NULL
,	NULL
and	NULL
E2F4	NULL
and	NULL
5	NULL
with	NULL
p107	NULL
and	NULL
p130	NULL
,	NULL
we	NULL
show	NULL
here	NULL
that	NULL
E2F4	NULL
and	NULL
DP	NULL
heterodimers	NULL
bind	NULL
largely	NULL
to	NULL
pRB	NULL
in	NULL
B-lymphocytes	NULL
in	NULL
G	NULL
,	NULL
and	NULL
G	NULL
,	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
findings	NULL
is	NULL
the	NULL
previous	NULL
observation	NULL
that	NULL
E2F4	NULL
also	NULL
complexes	NULL
with	NULL
pRB	NULL
as	NULL
well	NULL
as	NULL
p130	NULL
in	NULL
Daudi	NULL
B	NULL
cells	NULL
during	NULL
cell	NULL
cycle	NULL
arrest	NULL
caused	NULL
by	NULL
«	NULL
interferon	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Similar	NULL
pRB-E2F4-DP	NULL
complexes	NULL
have	NULL
also	NULL
been	NULL
detected	NULL
in	NULL
T-lymphocytes	NULL
(	NULL
27	NULL
)	NULL
but	NULL
not	NULL
until	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
phases	NULL
.	NULL

Expression	NULL
of	NULL
E2F	NULL
Components	NULL
after	NULL
PMA	NULL
Stimulation-To	NULL
investigate	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
these	NULL
changes	NULL
in	NULL
E2F	NULL
complexes	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
individual	NULL
E2F	NULL
components	NULL
identified	NULL
by	NULL
the	NULL
mobility	NULL
shift	NULL
supershift	NULL
experiments	NULL
was	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

Despite	NULL
a	NULL
wealth	NULL
of	NULL
knowledge	NULL
on	NULL
how	NULL
different	NULL
E2F	NULL
proteins	NULL
are	NULL
regulated	NULL
during	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
little	NULL
information	NULL
is	NULL
available	NULL
for	NULL
their	NULL
het-erodimeric	NULL
partners	NULL
,	NULL
DP1	NULL
and	NULL
-2	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
have	NULL
raised	NULL
monoclonal	NULL
and	NULL
polyclonal	NULL
antibodies	NULL
specifically	NULL
recognizing	NULL
individual	NULL
DP	NULL
proteins	NULL
.	NULL

The	NULL
Western	NULL
blot	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
showed	NULL
that	NULL
E2F1	NULL
,	NULL
E2F3	NULL
,	NULL
E2F4	NULL
,	NULL
DP1	NULL
,	NULL
and	NULL
DP2	NULL
were	NULL
expressed	NULL
in	NULL
B-lymphocytes	NULL
but	NULL
at	NULL
distinct	NULL
stages	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

However	NULL
,	NULL
although	NULL
we	NULL
could	NULL
detect	NULL
E2F2	NULL
and	NULL
-5	NULL
in	NULL
E2F	NULL
complexes	NULL
by	NULL
supershift	NULL
analysis	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
document	NULL
their	NULL
expression	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
because	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
mobility	NULL
shift	NULL
assays	NULL
are	NULL
more	NULL
sensitive	NULL
than	NULL
Western	NULL
blotting	NULL
.	NULL

E2F4	NULL
is	NULL
present	NULL
as	NULL
cells	NULL
traversed	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
,	NULL
but	NULL
the	NULL
relative	NULL
abundance	NULL
of	NULL
the	NULL
different	NULL
forms	NULL
of	NULL
12013	NULL
E2F4	NULL
changed	NULL
during	NULL
this	NULL
period	NULL
.	NULL

In	NULL
Gy	NULL
,	NULL
,	NULL
E2F4	NULL
was	NULL
visible	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
as	NULL
multiple	NULL
bands	NULL
with	NULL
different	NULL
electromobility	NULL
(	NULL
54-64	NULL
kDa	NULL
)	NULL
.	NULL

Upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
the	NULL
slower	NULL
migrating	NULL
forms	NULL
gradually	NULL
disappeared	NULL
,	NULL
and	NULL
the	NULL
two	NULL
fastest	NULL
migrating	NULL
species	NULL
predominated	NULL
for	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
time	NULL
course	NULL
.	NULL

Like	NULL
E2F4	NULL
,	NULL
DP1	NULL
and	NULL
DP2	NULL
were	NULL
present	NULL
throughout	NULL
the	NULL
time	NULL
course	NULL
,	NULL
and	NULL
similar	NULL
to	NULL
E2F4	NULL
,	NULL
both	NULL
DP1	NULL
and	NULL
DP2	NULL
underwent	NULL
electromobility	NULL
changes	NULL
when	NULL
the	NULL
cells	NULL
exited	NULL
G	NULL
,	NULL
.	NULL

In	NULL
unstimulated	NULL
B-lymphocytes	NULL
,	NULL
the	NULL
anti-DP1	NULL
antibody	NULL
recognized	NULL
a	NULL
protein	NULL
of	NULL
approximately	NULL
52	NULL
kDa	NULL
,	NULL
which	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
increased	NULL
its	NULL
migration	NULL
rate	NULL
as	NULL
cells	NULL
entered	NULL
G	NULL
,	NULL
from	NULL
G	NULL
,	NULL
(	NULL
12-48	NULL
h	NULL
;	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
6	NULL
)	NULL
and	NULL
persisted	NULL
in	NULL
this	NULL
high	NULL
mobility	NULL
form	NULL
throughout	NULL
late	NULL
G	NULL
;	NULL
(	NULL
48	NULL
h	NULL
)	NULL
and	NULL
into	NULL
S	NULL
(	NULL
72	NULL
h	NULL
)	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
total	NULL
DPI	NULL
level	NULL
as	NULL
the	NULL
cells	NULL
traversed	NULL
into	NULL
late	NULL
G	NULL
,	NULL
(	NULL
48	NULL
h	NULL
)	NULL
.	NULL

In	NULL
G	NULL
,	NULL
,	NULL
the	NULL
anti-DP2	NULL
monoclonal	NULL
antibody	NULL
recognized	NULL
3	NULL
doublets	NULL
of	NULL
apparent	NULL
molecular	NULL
masses	NULL
of	NULL
approximately	NULL
55	NULL
,	NULL
48	NULL
,	NULL
and	NULL
43	NULL
kDa	NULL
,	NULL
and	NULL
the	NULL
faster	NULL
migrating	NULL
forms	NULL
of	NULL
each	NULL
proteins	NULL
predominated	NULL
as	NULL
cells	NULL
entered	NULL
G	NULL
,	NULL
(	NULL
12-24	NULL
h	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
showing	NULL
that	NULL
DP2	NULL
exists	NULL
in	NULL
vivo	NULL
as	NULL
three	NULL
related	NULL
proteins	NULL
of	NULL
the	NULL
above	NULL
deduced	NULL
molecular	NULL
masses	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
doublets	NULL
could	NULL
represent	NULL
the	NULL
respective	NULL
hyper-	NULL
and	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
the	NULL
three	NULL
species	NULL
of	NULL
DP2	NULL
proteins	NULL
.	NULL

It	NULL
is	NULL
notable	NULL
that	NULL
the	NULL
kinetics	NULL
for	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
pRB	NULL
or	NULL
p130-E2F4-DP1	NULL
complex	NULL
mirrors	NULL
the	NULL
expression	NULL
patterns	NULL
of	NULL
slower	NULL
migrating	NULL
forms	NULL
of	NULL
both	NULL
DPL	NULL
or	NULL
DP2	NULL
and	NULL
E2F4	NULL
during	NULL
G	NULL
,	NULL
and	NULL
G	NULL
,	NULL
(	NULL
0-48	NULL
h	NULL
post-PMA	NULL
treat-ment	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
slower	NULL
migrating	NULL
species	NULL
of	NULL
DP	NULL
proteins	NULL
and	NULL
E2F4	NULL
could	NULL
be	NULL
rate-limiting	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
pRB-	NULL
or	NULL
p130-containing	NULL
E2F	NULL
complexes	NULL
during	NULL
that	NULL
period	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
the	NULL
immediate-early	NULL
response	NULL
gene	NULL
c-myc	NULL
is	NULL
expressed	NULL
rapidly	NULL
and	NULL
transiently	NULL
in	NULL
early	NULL
G	NULL
;	NULL
after	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
B-	NULL
and	NULL
T-lymphocytes	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
.	NULL

To	NULL
demonstrate	NULL
further	NULL
that	NULL
the	NULL
freshly	NULL
isolated	NULL
B-lymphocytes	NULL
are	NULL
in	NULL
a	NULL
quiescent	NULL
(	NULL
G	NULL
,	NULL
)	NULL
state	NULL
and	NULL
to	NULL
verify	NULL
the	NULL
kinetics	NULL
of	NULL
cell	NULL
cycle	NULL
entry	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
c-MYC	NULL
protein	NULL
before	NULL
and	NULL
after	NULL
PMA	NULL
stimulation	NULL
.	NULL

The	NULL
results	NULL
showed	NULL
that	NULL
e-mye	NULL
was	NULL
not	NULL
expressed	NULL
in	NULL
untreated	NULL
cells	NULL
but	NULL
was	NULL
significantly	NULL
induced	NULL
at	NULL
12	NULL
h	NULL
after	NULL
stimulation	NULL
with	NULL
PMA	NULL
before	NULL
being	NULL
down-regulated	NULL
thereafter	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
expression	NULL
of	NULL
c-MYC	NULL
is	NULL
necessary	NULL
for	NULL
cell	NULL
cycle	NULL
entry	NULL
,	NULL
these	NULL
data	NULL
,	NULL
together	NULL
with	NULL
the	NULL
increase	NULL
in	NULL
cellular	NULL
protein	NULL
content	NULL
,	NULL
are	NULL
consistent	NULL
with	NULL
co-ordinated	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
as	NULL
well	NULL
as	NULL
the	NULL
growth	NULL
cycle	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
pRB	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
p130	NULL
during	NULL
the	NULL
G	NULL
,	NULL
,	NULL
to	NULL
G	NULL
,	NULL
Transition-We	NULL
also	NULL
investigated	NULL
the	NULL
expression	NULL
and	NULL
phosphorylation	NULL
status	NULL
of	NULL
the	NULL
pocket	NULL
proteins	NULL
in	NULL
these	NULL
PMA-stimulated	NULL
B-lymphocytes	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

In	NULL
G	NULL
,	NULL
,	NULL
,	NULL
both	NULL
pRB	NULL
and	NULL
p130	NULL
are	NULL
present	NULL
in	NULL
their	NULL
respective	NULL
faster-migrating	NULL
,	NULL
hypophosphorylated	NULL
forms	NULL
.	NULL

After	NULL
PMA	NULL
stimulation	NULL
,	NULL
the	NULL
expression	NULL
levels	NULL
of	NULL
pRB	NULL
and	NULL
p130	NULL
increased	NULL
as	NULL
cells	NULL
traversed	NULL
from	NULL
G	NULL
,	NULL
into	NULL
G	NULL
,	NULL
.	NULL

Slower	NULL
migrating	NULL
hyperphosphorylated	NULL
forms	NULL
of	NULL
pRB	NULL
and	NULL
p130	NULL
could	NULL
be	NULL
detected	NULL
as	NULL
early	NULL
as	NULL
12	NULL
h	NULL
after	NULL
PMA	NULL
stimulation	NULL
and	NULL
became	NULL
more	NULL
abundant	NULL
as	NULL
the	NULL
cells	NULL
progressed	NULL
toward	NULL
the	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
same	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
pRB	NULL
and	NULL
p130	NULL
were	NULL
also	NULL
present	NULL
in	NULL
B-lymphocytes	NULL
isolated	NULL
by	NULL
a	NULL
different	NULL
method	NULL
(	NULL
cell	NULL
sorting	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
1st	NULL
lane	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
method	NULL
of	NULL
isolation	NULL
does	NULL
not	NULL
significantly	NULL
perturb	NULL
B-lymphocyte	NULL
quiescence	NULL
.	NULL

After	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
hyperphosphorylated	NULL
forms	NULL
of	NULL
pRB	NULL
and	NULL
p130	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
coincides	NULL
with	NULL
the	NULL
decrease	NULL
of	NULL
the	NULL
respective	NULL
pRB-	NULL
and	NULL
p130-containing	NULL
E2F	NULL
complexes	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
G	NULL
,	NULL
to	NULL
late	NULL
G4	NULL
.	NULL

Changes	NULL
in	NULL
Mobility	NULL
of	NULL
DP	NULL
Proteins	NULL
and	NULL
E2F4	NULL
as	NULL
Cells	NULL
Exit	NULL
G	NULL
,	NULL
Is	NULL
a	NULL
Result	NULL
of	NULL
Dephosphorylation-It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
changes	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
of	NULL
the	NULL
E2F4	NULL
and	NULL
DP	NULL
proteins	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
could	NULL
be	NULL
because	NULL
of	NULL
changes	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
12014	NULL
A	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
0	NULL
12	NULL
24	NULL
30	NULL
36	NULL
42	NULL
48	NULL
60	NULL
72	NULL
p130	NULL
|	NULL
is	NULL
»	NULL
,	NULL
wa	NULL
i	NULL
Hui-H	NULL
``	NULL
p107	NULL
-	NULL
way	NULL
wey	NULL
ty	NULL
y	NULL
ep	NULL
ap	NULL
-	NULL
:	NULL
__	NULL
B	NULL
-x	NULL
_	NULL
3	NULL
.	NULL

0	NULL
0	NULL
36	NULL
48	NULL
(	NULL
h	NULL
)	NULL
p30	NULL
(	NULL
ps	NULL
as	NULL
oa	NULL
PQ	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
pocket	NULL
protein	NULL
expression	NULL
in	NULL
B-lymphocytes	NULL
after	NULL
PMA	NULL
treatment	NULL
.	NULL

A	NULL
,	NULL
extracts	NULL
prepared	NULL
from	NULL
cells	NULL
at	NULL
different	NULL
times	NULL
after	NULL
PMA	NULL
stimulation	NULL
were	NULL
resolved	NULL
on	NULL
5	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
and	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
pRB	NULL
,	NULL
p107	NULL
,	NULL
and	NULL
p1830	NULL
.	NULL

The	NULL
hyper-	NULL
and	NULL
hypophosphorylated	NULL
forms	NULL
of	NULL
each	NULL
pocket	NULL
protein	NULL
are	NULL
represented	NULL
by	NULL
the	NULL
top	NULL
and	NULL
bottom	NULL
bands	NULL
,	NULL
respectively	NULL
.	NULL

B	NULL
,	NULL
extracts	NULL
prepared	NULL
from	NULL
unstimulated	NULL
small	NULL
dense	NULL
B-lymphocytes	NULL
enriched	NULL
by	NULL
cell	NULL
sorting	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
and	NULL
those	NULL
from	NULL
cells	NULL
isolated	NULL
using	NULL
anti-CD19-conjugated	NULL
magnetic	NULL
beads	NULL
(	NULL
lane	NULL
2-4	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
represent	NULL
B-lymphocytes	NULL
stimulated	NULL
with	NULL
PMA	NULL
for	NULL
0	NULL
,	NULL
86	NULL
,	NULL
and	NULL
48	NULL
h	NULL
,	NULL
respectively	NULL
.	NULL

in	NULL
their	NULL
phosphorylation	NULL
status	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
these	NULL
electrophoretic	NULL
mobility	NULL
changes	NULL
are	NULL
the	NULL
result	NULL
of	NULL
dephosphorylation	NULL
,	NULL
whole	NULL
cell	NULL
lysates	NULL
from	NULL
B-lymphocytes	NULL
at	NULL
G	NULL
,	NULL
(	NULL
0	NULL
h	NULL
)	NULL
and	NULL
late	NULL
G	NULL
;	NULL
(	NULL
48	NULL
h	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
A	NULL
phosphatase	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
converted	NULL
the	NULL
slower	NULL
migrating	NULL
DP1	NULL
from	NULL
unstimulated	NULL
quiescent	NULL
B-lymphocytes	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lst	NULL
lane	NULL
)	NULL
to	NULL
a	NULL
faster	NULL
migrating	NULL
form	NULL
(	NULL
2nd	NULL
lane	NULL
)	NULL
with	NULL
similar	NULL
mobility	NULL
to	NULL
the	NULL
DPI	NULL
protein	NULL
detected	NULL
at	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
DPI	NULL
is	NULL
present	NULL
in	NULL
a	NULL
hyperphosphorylated	NULL
form	NULL
in	NULL
G	NULL
,	NULL
phase	NULL
and	NULL
becomes	NULL
dephosphorylated	NULL
as	NULL
cells	NULL
progress	NULL
from	NULL
G	NULL
,	NULL
into	NULL
G	NULL
,	NULL
phase	NULL
.	NULL

Similar	NULL
phosphatase	NULL
treatment	NULL
failed	NULL
to	NULL
produce	NULL
a	NULL
detectable	NULL
electrophoretic	NULL
mobility	NULL
change	NULL
in	NULL
DP1	NULL
derived	NULL
from	NULL
cells	NULL
in	NULL
late	NULL
G	NULL
;	NULL
phase	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
4th	NULL
lane	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
DP1	NULL
protein	NULL
present	NULL
in	NULL
late	NULL
G	NULL
,	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
an	NULL
unphosphorylated	NULL
form	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
also	NULL
turned	NULL
E2F4	NULL
proteins	NULL
from	NULL
both	NULL
G	NULL
,	NULL
and	NULL
G	NULL
phases	NULL
into	NULL
a	NULL
faster	NULL
migrating	NULL
form	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
dephosphorylated	NULL
form	NULL
of	NULL
E2F4	NULL
had	NULL
higher	NULL
mobility	NULL
than	NULL
those	NULL
species	NULL
observed	NULL
in	NULL
either	NULL
G	NULL
,	NULL
or	NULL
G	NULL
,	NULL
/8	NULL
,	NULL
indicating	NULL
that	NULL
E2F4	NULL
changes	NULL
from	NULL
hyperphosphorylated	NULL
to	NULL
hypophosphorylated	NULL
forms	NULL
as	NULL
cells	NULL
progress	NULL
from	NULL
G	NULL
,	NULL
into	NULL
late	NULL
G	NULL
;	NULL
.	NULL

Although	NULL
these	NULL
forms	NULL
of	NULL
E2F4	NULL
in	NULL
late	NULL
G	NULL
,	NULL
and	NULL
S	NULL
are	NULL
hypophosphorylated	NULL
,	NULL
they	NULL
are	NULL
not	NULL
unphosphorylated	NULL
,	NULL
as	NULL
phosphatase	NULL
treatment	NULL
can	NULL
further	NULL
increase	NULL
their	NULL
mobility	NULL
.	NULL

Similarly	NULL
,	NULL
phosphatase	NULL
treatment	NULL
also	NULL
resulted	NULL
in	NULL
the	NULL
disappearance	NULL
of	NULL
the	NULL
apparent	NULL
higher	NULL
molecular	NULL
weight	NULL
forms	NULL
of	NULL
each	NULL
of	NULL
the	NULL
three	NULL
DP2	NULL
doublets	NULL
and	NULL
in	NULL
reciprocal	NULL
increases	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
corresponding	NULL
lower	NULL
molecular	NULL
weight	NULL
forms	NULL
.	NULL

These	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
that	NULL
all	NULL
three	NULL
DP2	NULL
polypeptides	NULL
are	NULL
phosphoproteins	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
kinetics	NULL
for	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
pRB-	NULL
or	NULL
p130-containing	NULL
G/G	NULL
,	NULL
E2F	NULL
complexes	NULL
parallels	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
slower	NULL
migrating	NULL
hyperphosphorylated	NULL
forms	NULL
of	NULL
DP1	NULL
,	NULL
DP2	NULL
,	NULL
and	NULL
E2F4	NULL
,	NULL
implying	NULL
that	NULL
the	NULL
phosphorylation	NULL
states	NULL
of	NULL
these	NULL
E2F	NULL
components	NULL
could	NULL
have	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
the	NULL
E2F	NULL
complexes	NULL
.	NULL

Hyperphosphorylated	NULL
Forms	NULL
of	NULL
DP1	NULL
and	NULL
E2F4	NULL
Preferentially	NULL
Bind	NULL
DNA-We	NULL
next	NULL
investigated	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
dephosphorylation	NULL
of	NULL
DP	NULL
and	NULL
E2F4	NULL
proteins	NULL
as	NULL
B-lymphocytes	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
performed	NULL
``	NULL
pull-down	NULL
``	NULL
experiments	NULL
using	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
contain	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
A	NULL
A	NULL
0	NULL
0	NULL
48	NULL
48	NULL
(	NULL
®	NULL
)	NULL
«	NULL
aw	NULL
*~	NULL
.	NULL

«	NULL
gn	NULL
DP1	NULL
C	NULL
'-	NULL
'	NULL
z	NULL
E2F4	NULL
[	NULL
§=.i*	NULL
conn	NULL
C	NULL
%	NULL
DP2	NULL
C	NULL
Ste	NULL
ame	NULL
C	NULL
~	NULL
»	NULL
CHD	NULL
CW	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Phosphatase	NULL
treatment	NULL
of	NULL
human	NULL
B-lymphocyte	NULL
extracts	NULL
.	NULL

Whole	NULL
cell	NULL
extracts	NULL
derived	NULL
from	NULL
human	NULL
B-lymphocytes	NULL
at	NULL
0	NULL
and	NULL
48	NULL
h	NULL
after	NULL
PMA	NULL
treatment	NULL
were	NULL
incubated	NULL
with	NULL
A	NULL
phosphatase	NULL
at	NULL
30	NULL
°C	NULL
for	NULL
1	NULL
h.	NULL
After	NULL
phosphatase	NULL
treatment	NULL
,	NULL
extracts	NULL
were	NULL
Western-blotted	NULL
with	NULL
antibodies	NULL
against	NULL
DP1	NULL
,	NULL
DP2	NULL
,	NULL
and	NULL
E2F4	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
.	NULL

ing	NULL
an	NULL
E2F	NULL
site	NULL
conjugated	NULL
to	NULL
biotin	NULL
.	NULL

This	NULL
was	NULL
captured	NULL
using	NULL
avidin	NULL
resin	NULL
,	NULL
and	NULL
the	NULL
proteins	NULL
thus	NULL
isolated	NULL
were	NULL
assessed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
E2F	NULL
binding	NULL
site	NULL
containing	NULL
oligonucleotides	NULL
were	NULL
incubated	NULL
with	NULL
lysates	NULL
from	NULL
B-lymphocytes	NULL
stimulated	NULL
with	NULL
PMA	NULL
for	NULL
0	NULL
,	NULL
12	NULL
,	NULL
and	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
pull-down	NULL
results	NULL
indicated	NULL
that	NULL
only	NULL
the	NULL
hyperphosphorylated	NULL
form	NULL
of	NULL
DP1	NULL
bound	NULL
to	NULL
DNA	NULL
under	NULL
our	NULL
experimental	NULL
con-ditions	NULL
.	NULL

To	NULL
confirm	NULL
this	NULL
finding	NULL
,	NULL
we	NULL
extended	NULL
our	NULL
pull-down	NULL
experiments	NULL
to	NULL
lysates	NULL
from	NULL
B-lymphocytes	NULL
in	NULL
mid	NULL
to	NULL
late	NULL
G	NULL
;	NULL
phase	NULL
(	NULL
24	NULL
,	NULL
36	NULL
,	NULL
and	NULL
48	NULL
h	NULL
after	NULL
PMA	NULL
)	NULL
,	NULL
when	NULL
DP1	NULL
became	NULL
progressively	NULL
hypophosphorylated	NULL
.	NULL

Consistent	NULL
with	NULL
earlier	NULL
results	NULL
,	NULL
only	NULL
the	NULL
hyperphosphorylated	NULL
form	NULL
of	NULL
DP1	NULL
associated	NULL
with	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
also	NULL
detected	NULL
a	NULL
down-regulation	NULL
of	NULL
DP1	NULL
DNA	NULL
binding	NULL
activity	NULL
,	NULL
despite	NULL
a	NULL
general	NULL
increase	NULL
in	NULL
DP-1	NULL
protein	NULL
expression	NULL
at	NULL
late	NULL
G	NULL
,	NULL
(	NULL
48	NULL
h	NULL
)	NULL
.	NULL

This	NULL
decrease	NULL
in	NULL
DNA	NULL
binding	NULL
is	NULL
attributable	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
DP-1	NULL
is	NULL
present	NULL
predominantly	NULL
in	NULL
the	NULL
non-DNA	NULL
binding	NULL
,	NULL
hypophosphorylated	NULL
form	NULL
in	NULL
late	NULL
G	NULL
;	NULL
(	NULL
48	NULL
h	NULL
after	NULL
PMA	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
further	NULL
supports	NULL
the	NULL
idea	NULL
that	NULL
in	NULL
G	NULL
,	NULL
,	NULL
only	NULL
the	NULL
hypophosphorylated	NULL
DP1	NULL
binds	NULL
DNA	NULL
.	NULL

Binding	NULL
was	NULL
E2F	NULL
site-specific	NULL
,	NULL
because	NULL
no	NULL
detectable	NULL
E2F	NULL
activity	NULL
was	NULL
pulled	NULL
down	NULL
by	NULL
a	NULL
similar	NULL
oligonucleotide	NULL
with	NULL
the	NULL
E2F	NULL
site	NULL
mutated	NULL
.	NULL

The	NULL
results	NULL
also	NULL
demonstrated	NULL
that	NULL
the	NULL
E2F4	NULL
species	NULL
with	NULL
higher	NULL
apparent	NULL
molecular	NULL
masses	NULL
bound	NULL
preferentially	NULL
to	NULL
DNA	NULL
,	NULL
in	NULL
comparison	NULL
with	NULL
the	NULL
faster	NULL
migrating	NULL
forms	NULL
.	NULL

We	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
DP2	NULL
in	NULL
the	NULL
complexes	NULL
pulled	NULL
down	NULL
by	NULL
this	NULL
method	NULL
,	NULL
which	NULL
possibly	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
DP2	NULL
is	NULL
only	NULL
a	NULL
very	NULL
minor	NULL
component	NULL
of	NULL
the	NULL
E2F	NULL
heterodimers	NULL
in	NULL
human	NULL
B-lymphocytes	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
identified	NULL
and	NULL
monitored	NULL
the	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
in	NULL
primary	NULL
B-lymphocytes	NULL
that	NULL
had	NULL
been	NULL
induced	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
with	NULL
PMA	NULL
.	NULL

We	NULL
also	NULL
further	NULL
investigated	NULL
the	NULL
underlying	NULL
mechanisms	NULL
regulating	NULL
the	NULL
formation	NULL
and	NULL
disassembly	NULL
of	NULL
these	NULL
E2F	NULL
complexes	NULL
.	NULL

We	NULL
have	NULL
used	NULL
human	NULL
B-lymphocytes	NULL
as	NULL
a	NULL
model	NULL
for	NULL
primary	NULL
quiescent	NULL
cells	NULL
because	NULL
they	NULL
can	NULL
be	NULL
isolated	NULL
to	NULL
a	NULL
high	NULL
degree	NULL
of	NULL
purity	NULL
and	NULL
have	NULL
an	NULL
extended	NULL
G	NULL
,	NULL
phase	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
T	NULL
lymphocytes	NULL
,	NULL
which	NULL
are	NULL
well	NULL
studied	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
molecular	NULL
mechanisms	NULL
in	NULL
B	NULL
lymphocytes	NULL
that	NULL
regulate	NULL
entry	NULL
into	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

It	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
that	NULL
B-lymphocytes	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
anti-CD19	NULL
;	NULL
therefore	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
isolation	NULL
of	NULL
B-lymphocytes	NULL
by	NULL
positive	NULL
selection	NULL
with	NULL
anti-CD19-coupled	NULL
magnetic	NULL
beads	NULL
could	NULL
potentially	NULL
stimulate	NULL
quiescent	NULL
B-lymphocytes	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

We	NULL
have	NULL
guarded	NULL
against	NULL
this	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
Extract	NULL
wtE2F	NULL
mut	NULL
E2F	NULL
0	NULL
12	NULL
24	NULL
0	NULL
12	NULL
24	NULL
0	NULL
12	NULL
24	NULL
(	NULL
h	NULL
)	NULL
pri-	NULL
*	NULL
PHD	NULL
cri	NULL
:	NULL
Bm	NULL
°	NULL
C	NULL
#	NULL
#	NULL
Extract	NULL
wtE2F	NULL
mut	NULL
E2F	NULL
24	NULL
36	NULL
48	NULL
24	NULL
36	NULL
48	NULL
24	NULL
36	NULL
48	NULL
(	NULL
h	NULL
)	NULL
DP	NULL
i-	NULL
@	NULL
apa	NULL
®	NULL
*	NULL
.	NULL

~	NULL
iulie	NULL
i	NULL
1000	NULL
..	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Assay	NULL
of	NULL
E2F-DNA	NULL
binding	NULL
activity	NULL
in	NULL
human	NULL
B-lymphocyte	NULL
extracts	NULL
.	NULL

Proteins	NULL
in	NULL
whole	NULL
cell	NULL
extracts	NULL
prepared	NULL
from	NULL
B-lymphocytes	NULL
after	NULL
PMA	NULL
treatment	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
were	NULL
bound	NULL
to	NULL
bioti-nylated	NULL
double-stranded	NULL
oligonucleotides	NULL
containing	NULL
either	NULL
the	NULL
wild-type	NULL
(	NULL
w	NULL
?	NULL
)	NULL

or	NULL
mutant	NULL
E2F	NULL
sites	NULL
and	NULL
isolated	NULL
on	NULL
avidin-conjugated	NULL
beads	NULL
.	NULL

The	NULL
proteins	NULL
captured	NULL
by	NULL
the	NULL
oligonucleotides	NULL
were	NULL
then	NULL
resolved	NULL
by	NULL
SDS-acrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
Western-blotted	NULL
with	NULL
antibodies	NULL
against	NULL
DP1	NULL
and	NULL
E2F4	NULL
.	NULL

One-tenth	NULL
of	NULL
the	NULL
original	NULL
extracts	NULL
were	NULL
included	NULL
as	NULL
controls	NULL
(	NULL
Zanes	NULL
1-3	NULL
in	NULL
both	NULL
upper	NULL
panel	NULL
and	NULL
lower	NULL
panels	NULL
)	NULL
.	NULL

possibility	NULL
by	NULL
incubating	NULL
the	NULL
freshly	NULL
isolated	NULL
cells	NULL
for	NULL
36	NULL
h	NULL
without	NULL
stimulus	NULL
to	NULL
allow	NULL
existing	NULL
proliferative	NULL
signals	NULL
in	NULL
these	NULL
cells	NULL
to	NULL
decay	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
the	NULL
B-lymphocytes	NULL
isolated	NULL
are	NULL
in	NULL
quiescent	NULL
(	NULL
G	NULL
,	NULL
)	NULL
phase	NULL
.	NULL

First	NULL
,	NULL
the	NULL
immediate-early	NULL
gene	NULL
c-myc	NULL
was	NULL
not	NULL
expressed	NULL
in	NULL
untreated	NULL
cells	NULL
but	NULL
was	NULL
induced	NULL
rapidly	NULL
after	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
to	NULL
enter	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
PMA	NULL
.	NULL

Second	NULL
,	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
detect	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
p130-E2F	NULL
complex	NULL
,	NULL
which	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
unique	NULL
to	NULL
cells	NULL
in	NULL
G	NULL
,	NULL
.	NULL

Third	NULL
,	NULL
flow	NULL
cytometric	NULL
analysis	NULL
showed	NULL
that	NULL
these	NULL
cells	NULL
have	NULL
a	NULL
low	NULL
protein	NULL
content	NULL
and	NULL
a	NULL
2N	NULL
DNA	NULL
content	NULL
,	NULL
indicative	NULL
of	NULL
cells	NULL
resting	NULL
in	NULL
G	NULL
,	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
B-lymphocytes	NULL
prepared	NULL
by	NULL
negative	NULL
selection	NULL
also	NULL
showed	NULL
the	NULL
same	NULL
expression	NULL
pattern	NULL
and	NULL
phosphorylation	NULL
status	NULL
for	NULL
pRB	NULL
and	NULL
p130	NULL
as	NULL
the	NULL
cells	NULL
isolated	NULL
by	NULL
positive	NULL
selection	NULL
using	NULL
anti-CD19	NULL
beads	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
cells	NULL
represent	NULL
a	NULL
highly	NULL
homogeneous	NULL
population	NULL
of	NULL
quiescent	NULL
cells	NULL
at	NULL
the	NULL
start	NULL
of	NULL
the	NULL
experiments	NULL
.	NULL

Although	NULL
previous	NULL
reports	NULL
have	NULL
indicated	NULL
that	NULL
E2F4-con-taining	NULL
E2F	NULL
heterodimers	NULL
preferentially	NULL
complex	NULL
with	NULL
p107	NULL
and	NULL
p130	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
14	NULL
)	NULL
and	NULL
that	NULL
p130	NULL
is	NULL
the	NULL
predominant	NULL
pocket	NULL
protein	NULL
present	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
27	NULL
,	NULL
28	NULL
,	NULL
48	NULL
,	NULL
55	NULL
)	NULL
,	NULL
our	NULL
bandshift	NULL
and	NULL
supershift	NULL
experiments	NULL
showed	NULL
that	NULL
the	NULL
major	NULL
species	NULL
of	NULL
EZ2F	NULL
complex	NULL
in	NULL
B-lymphocytes	NULL
in	NULL
G	NULL
,	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
consists	NULL
of	NULL
pRB	NULL
binding	NULL
to	NULL
E2F4	NULL
and	NULL
DPI	NULL
or	NULL
DP2	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
detection	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
hypophosphorylated	NULL
(	NULL
E2F	NULL
binding	NULL
)	NULL
forms	NULL
of	NULL
pRB	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
;	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Although	NULL
pRB-E2F4-containing	NULL
complexes	NULL
have	NULL
previously	NULL
been	NULL
reported	NULL
in	NULL
human	NULL
T-lymphocytes	NULL
in	NULL
G	NULL
;	NULL
and	NULL
S	NULL
phases	NULL
and	NULL
in	NULL
quiescent	NULL
T-lymphocytes	NULL
derived	NULL
from	NULL
mice	NULL
deficient	NULL
for	NULL
p130	NULL
,	NULL
to	NULL
our	NULL
knowledge	NULL
this	NULL
is	NULL
the	NULL
first	NULL
documentation	NULL
of	NULL
pRB	NULL
complexing	NULL
with	NULL
E2F4	NULL
in	NULL
normal	NULL
quiescent	NULL
(	NULL
G	NULL
,	NULL
,	NULL
)	NULL
primary	NULL
cells	NULL
.	NULL

This	NULL
observation	NULL
indicates	NULL
that	NULL
the	NULL
pRB-E2F4-DP1	NULL
complex	NULL
does	NULL
exist	NULL
in	NULL
primary	NULL
cells	NULL
and	NULL
is	NULL
not	NULL
an	NULL
artifact	NULL
of	NULL
tissue	NULL
culture	NULL
cell	NULL
lines	NULL
and	NULL
could	NULL
have	NULL
a	NULL
role	NULL
in	NULL
maintaining	NULL
the	NULL
quiescent	NULL
state	NULL
as	NULL
suggested	NULL
by	NULL
Ikeda	NULL
et	NULL
al	NULL
.	NULL

(	NULL
56	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
this	NULL
pRB-E2F4-DP1	NULL
complex	NULL
is	NULL
unclear	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
to	NULL
have	NULL
a	NULL
similar	NULL
transcrip-	NULL
12015	NULL
tion	NULL
repression	NULL
function	NULL
as	NULL
the	NULL
p130-E2F4	NULL
complex	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
deduction	NULL
are	NULL
previous	NULL
gene	NULL
``	NULL
knock-out	NULL
``	NULL
experiments	NULL
for	NULL
the	NULL
pocket	NULL
proteins	NULL
,	NULL
revealing	NULL
that	NULL
the	NULL
expression	NULL
levels	NULL
of	NULL
individual	NULL
pocket	NULL
proteins	NULL
are	NULL
interlinked	NULL
and	NULL
that	NULL
,	NULL
in	NULL
mice	NULL
deficient	NULL
for	NULL
p130	NULL
,	NULL
there	NULL
is	NULL
an	NULL
up-regulation	NULL
of	NULL
pRB	NULL
and/or	NULL
p107	NULL
to	NULL
compensate	NULL
for	NULL
its	NULL
function	NULL
in	NULL
G	NULL
,	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
pRB-E2F	NULL
complexes	NULL
are	NULL
increased	NULL
in	NULL
quiescent	NULL
p130-deficient	NULL
(	NULL
-/-	NULL
)	NULL
T-lymphocytes	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
reason	NULL
for	NULL
this	NULL
is	NULL
as	NULL
yet	NULL
unclear	NULL
;	NULL
however	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
because	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
both	NULL
pRB	NULL
and	NULL
p107	NULL
are	NULL
E2F-regulated	NULL
genes	NULL
,	NULL
and	NULL
their	NULL
expression	NULL
is	NULL
negatively	NULL
controlled	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
p130	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
high	NULL
levels	NULL
of	NULL
pRB	NULL
observed	NULL
in	NULL
quiescent	NULL
(	NULL
G	NULL
,	NULL
)	NULL
human	NULL
B-lymphocytes	NULL
could	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
p130	NULL
expressed	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

A	NULL
very	NULL
similar	NULL
scenario	NULL
where	NULL
high	NULL
levels	NULL
of	NULL
pRB-contain-ing	NULL
E2F4	NULL
complexes	NULL
coexist	NULL
with	NULL
low	NULL
levels	NULL
of	NULL
p130-E2F4	NULL
complexes	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
in	NULL
differentiated	NULL
HL	NULL
60	NULL
cells	NULL
after	NULL
treatment	NULL
with	NULL
PMA	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
expression	NULL
levels	NULL
and	NULL
phosphorylation	NULL
states	NULL
of	NULL
the	NULL
pocket	NULL
proteins	NULL
are	NULL
important	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
transcriptional	NULL
repressive	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
.	NULL

Our	NULL
present	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
pocket	NULL
protein-E2F	NULL
complexes	NULL
also	NULL
depends	NULL
on	NULL
the	NULL
expression	NULL
levels	NULL
as	NULL
well	NULL
as	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
DP1	NULL
and	NULL
E2F4	NULL
.	NULL

This	NULL
suggestion	NULL
is	NULL
based	NULL
on	NULL
the	NULL
results	NULL
that	NULL
the	NULL
slower	NULL
migrating	NULL
hyperphosphorylated	NULL
forms	NULL
of	NULL
DPL	NULL
and	NULL
E2F4	NULL
bind	NULL
DNA	NULL
preferentially	NULL
,	NULL
and	NULL
these	NULL
hyperphosphorylated	NULL
DP1	NULL
and	NULL
E2F4	NULL
become	NULL
progressively	NULL
dephosphorylated	NULL
as	NULL
the	NULL
cells	NULL
progress	NULL
from	NULL
G	NULL
,	NULL
to	NULL
late	NULL
G	NULL
,	NULL
,	NULL
concomitant	NULL
with	NULL
a	NULL
parallel	NULL
decrease	NULL
in	NULL
levels	NULL
of	NULL
pRB-E2F	NULL
or	NULL
p130-E2F	NULL
complexes	NULL
.	NULL

Moreover	NULL
,	NULL
during	NULL
the	NULL
initial	NULL
G	NULL
,	NULL
to	NULL
early	NULL
G	NULL
,	NULL
traverse	NULL
,	NULL
the	NULL
kinetics	NULL
for	NULL
the	NULL
accumulation	NULL
in	NULL
levels	NULL
of	NULL
pRB-E2F	NULL
or	NULL
p130-E2F	NULL
complexes	NULL
also	NULL
coincides	NULL
with	NULL
the	NULL
elevation	NULL
of	NULL
DP1	NULL
and	NULL
E2F4	NULL
expression	NULL
.	NULL

In	NULL
conjunction	NULL
with	NULL
previous	NULL
published	NULL
results	NULL
,	NULL
our	NULL
findings	NULL
lead	NULL
us	NULL
to	NULL
postulate	NULL
that	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
;	NULL
,	NULL
the	NULL
hyperphosphorylated	NULL
forms	NULL
of	NULL
DP1	NULL
and	NULL
E2F4	NULL
tether	NULL
the	NULL
hypophosphorylated	NULL
pocket	NULL
proteins	NULL
to	NULL
E2F	NULL
DNA-binding	NULL
sites	NULL
to	NULL
repress	NULL
E2F-dependent	NULL
transcription	NULL
.	NULL

As	NULL
the	NULL
cells	NULL
progress	NULL
through	NULL
G	NULL
,	NULL
,	NULL
DP1	NULL
and	NULL
E2F4	NULL
become	NULL
progressively	NULL
hypophosphorylated	NULL
,	NULL
culminating	NULL
in	NULL
a	NULL
loss	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
and	NULL
derepression	NULL
of	NULL
promoters	NULL
negatively	NULL
regulated	NULL
through	NULL
E2F	NULL
sites	NULL
.	NULL

This	NULL
concept	NULL
is	NULL
compatible	NULL
with	NULL
the	NULL
in	NULL
vivo	NULL
footprinting	NULL
results	NULL
of	NULL
the	NULL
B-myb	NULL
,	NULL
cde2	NULL
,	NULL
and	NULL
cyclin	NULL
A	NULL
promoters	NULL
showing	NULL
that	NULL
the	NULL
E2F	NULL
sites	NULL
are	NULL
occupied	NULL
only	NULL
in	NULL
G	NULL
,	NULL
/early	NULL
G	NULL
,	NULL
but	NULL
not	NULL
late	NULL
phase	NULL
(	NULL
42-44	NULL
)	NULL
.	NULL

These	NULL
in	NULL
vivo	NULL
protection	NULL
patterns	NULL
are	NULL
at	NULL
variance	NULL
with	NULL
the	NULL
usual	NULL
mobility	NULL
shift	NULL
results	NULL
showing	NULL
that	NULL
the	NULL
E2F	NULL
sites	NULL
are	NULL
occupied	NULL
predominantly	NULL
by	NULL
high	NULL
levels	NULL
of	NULL
p107-E2F4-DP1-cyclin	NULL
A	NULL
complexes	NULL
during	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
disparity	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
because	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
low	NULL
stringency	NULL
conditions	NULL
used	NULL
for	NULL
mobility	NULL
shift	NULL
assays	NULL
can	NULL
detect	NULL
low	NULL
affinity	NULL
E2F	NULL
complexes	NULL
not	NULL
normally	NULL
found	NULL
on	NULL
these	NULL
endogenous	NULL
promoters	NULL
.	NULL

This	NULL
also	NULL
suggests	NULL
that	NULL
the	NULL
in	NULL
vitro	NULL
DNA	NULL
binding	NULL
experiments	NULL
do	NULL
not	NULL
necessarily	NULL
truly	NULL
reflect	NULL
the	NULL
binding	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
significance	NULL
of	NULL
this	NULL
regulatory	NULL
mechanism	NULL
,	NULL
particularly	NULL
in	NULL
B-lymphocytes	NULL
,	NULL
is	NULL
further	NULL
highlighted	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
there	NULL
is	NULL
a	NULL
lack	NULL
of	NULL
detectable	NULL
free	NULL
E2F	NULL
complexes	NULL
in	NULL
G	NULL
,	NULL
and	NULL
early	NULL
G	NULL
,	NULL
phases	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
pocket	NULL
proteins	NULL
are	NULL
present	NULL
in	NULL
excess	NULL
over	NULL
the	NULL
components	NULL
of	NULL
E2F	NULL
in	NULL
early	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
and	NULL
consequently	NULL
,	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
E2F	NULL
is	NULL
rate-limiting	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
complexed	NULL
E2F	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
present	NULL
findings	NULL
contribute	NULL
toward	NULL
defining	NULL
the	NULL
underlying	NULL
mechanisms	NULL
that	NULL
modulate	NULL
E2F	NULL
activity	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
cell	NULL
cycle	NULL
progression	NULL
during	NULL
the	NULL
G	NULL
,	NULL
to	NULL
S	NULL
transition	NULL
in	NULL
general	NULL
and	NULL
in	NULL
B-lymphocytes	NULL
in	NULL
particular	NULL
.	NULL

Through	NULL
our	NULL
study	NULL
,	NULL
we	NULL
also	NULL
uncover	NULL
and	NULL
provide	NULL
evidence	NULL
for	NULL
a	NULL
novel	NULL
and	NULL
potentially	NULL
important	NULL
mechanism	NULL
by	NULL
which	NULL
E2F	NULL
complexes	NULL
are	NULL
regulated	NULL
during	NULL
early	NULL
stages	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
12016	NULL
E2F	NULL
Complexes	NULL
in	NULL
B-lymphocytes	NULL
Acknowledgments-We	NULL
acknowledge	NULL
the	NULL
generosity	NULL
of	NULL
Professor	NULL
Nick	NULL
Dyson	NULL
,	NULL
Dr.	NULL
Antonio	NULL
Giordano	NULL
,	NULL
Dr.	NULL
Paulo	NULL
Claudio	NULL
,	NULL
Dr.	NULL
Jonathan	NULL
Pines	NULL
,	NULL
and	NULL
Dr.	NULL
Sybille	NULL
Mittnacht	NULL
in	NULL
providing	NULL
reagents	NULL
.	NULL

We	NULL
thank	NULL
Arnold	NULL
Pizzey	NULL
for	NULL
carrying	NULL
out	NULL
cell	NULL
cycle	NULL
analysis	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Dr.	NULL
John	NULL
Norton	NULL
and	NULL
Luke	NULL
Peterson	NULL
for	NULL
providing	NULL
the	NULL
fluorescence-activated	NULL
cell	NULL
sorted	NULL
B-lymphocytes	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Drs	NULL
.	NULL

Janet	NULL
Glassford	NULL
,	NULL
Manuel	NULL
Collado	NULL
,	NULL
and	NULL
Magali	NULL
Pariat	NULL
for	NULL
critical	NULL
comments	NULL
on	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
&	NULL
Bernards	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1287	NULL
,	NULL
103-120	NULL
.	NULL

Lam	NULL
,	NULL
E.	NULL
W.-F.	NULL
&	NULL
La	NULL
Thangue	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

6	NULL
,	NULL
859-866	NULL
.	NULL

Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
875-376	NULL
.	NULL

Dyson	NULL
,	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

12	NULL
,	NULL
2245-2262	NULL
.	NULL

Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cell	NULL
81	NULL
,	NULL
823-330	NULL
Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
Speck	NULL
,	NULL
S.	NULL
H.	NULL
&	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

90	NULL
,	NULL
6914-6918	NULL
Johnson	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Oncogene	NULL
11	NULL
,	NULL
1685-1692	NULL
.	NULL

Zamanian	NULL
,	NULL
M.	NULL
&	NULL
La	NULL
Thangue	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

Cell	NULL
4	NULL
,	NULL
389-396	NULL
.	NULL

Vairo	NULL
,	NULL
G.	NULL
,	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Ginsberg	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
869-881	NULL
.	NULL

Lees	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Saito	NULL
,	NULL
M.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Valentine	NULL
,	NULL
M.	NULL
,	NULL
Look	NULL
,	NULL
T.	NULL
,	NULL
Harlow	NULL
,	NULL
E.	NULL
,	NULL
Dyson	NULL
,	NULL
N.	NULL
&	NULL
Helin	NULL
,	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
7818-7825	NULL
11	NULL
.	NULL

Sardet	NULL
,	NULL
C.	NULL
,	NULL
Vidal	NULL
,	NULL
M.	NULL
,	NULL
Cobrinik	NULL
,	NULL
D.	NULL
,	NULL
Geng	NULL
,	NULL
Y.	NULL
,	NULL
Onufryk	NULL
,	NULL
C.	NULL
,	NULL
Chen	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
2408-2407	NULL
12	NULL
.	NULL

Hijmans	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Voorhoeve	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
va	NULL
n't	NULL
Veer	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

&	NULL
Bernards	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
3082-3089	NULL
13	NULL
.	NULL

Ginsberg	NULL
,	NULL
D.	NULL
,	NULL
Vairo	NULL
,	NULL
G.	NULL
,	NULL
Chittenden	NULL
,	NULL
T.	NULL
,	NULL
Xiao	NULL
,	NULL
Z.	NULL
X.	NULL
,	NULL
Xu	NULL
,	NULL
G.	NULL
,	NULL
Wydner	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Lawrence	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

8	NULL
,	NULL
2665-2679	NULL
14	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Kerkhoven	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Zhu	NULL
,	NULL
L.	NULL
,	NULL
Carlee	NULL
,	NULL
L.	NULL
,	NULL
Voorhoeve	NULL
,	NULL
P.	NULL
M.	NULL
&	NULL
Bernards	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

8	NULL
,	NULL
2680-2690	NULL
15	NULL
.	NULL

Cartwright	NULL
,	NULL
P.	NULL
,	NULL
Muller	NULL
,	NULL
H.	NULL
,	NULL
Wagener	NULL
,	NULL
C.	NULL
,	NULL
Holm	NULL
,	NULL
K.	NULL
&	NULL
Helin	NULL
,	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
Oncogene	NULL
17	NULL
,	NULL
611-623	NULL
16	NULL
.	NULL

Morkel	NULL
,	NULL
M.	NULL
,	NULL
Wenkel	NULL
,	NULL
J.	NULL
,	NULL
Bannister	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Kouzarides	NULL
,	NULL
T.	NULL
&	NULL
Hagemeier	NULL
,	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
890	NULL
,	NULL
567-568	NULL
17	NULL
.	NULL

Trimarchi	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Fairchild	NULL
,	NULL
B.	NULL
,	NULL
Verona	NULL
,	NULL
R.	NULL
,	NULL
Moberg	NULL
,	NULL
K.	NULL
,	NULL
Andon	NULL
,	NULL
N.	NULL
&	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

95	NULL
,	NULL
2850-2855	NULL
18	NULL
.	NULL

Dalton	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
1797-1804	NULL
19	NULL
.	NULL

Lam	NULL
,	NULL
E.	NULL
W.-F.	NULL
&	NULL
Watson	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
2705-2713	NULL
20	NULL
.	NULL

Lam	NULL
,	NULL
E.	NULL
W.-F.	NULL
,	NULL
Bennett	NULL
,	NULL
J.	NULL
D.	NULL
&	NULL
Watson	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Gene	NULL
160	NULL
,	NULL
277-281	NULL
21	NULL
.	NULL

Lam	NULL
,	NULL
E.	NULL
W.-F.	NULL
,	NULL
Morris	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Davies	NULL
,	NULL
R.	NULL
,	NULL
Crook	NULL
,	NULL
T.	NULL
,	NULL
Watson	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Vousden	NULL
,	NULL
K.	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
871-878	NULL
22	NULL
.	NULL

Neuman	NULL
,	NULL
E.	NULL
,	NULL
Flemington	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
Sellers	NULL
,	NULL
W.	NULL
R.	NULL
&	NULL
Kaelin	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Jr.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
6607-6615	NULL
23	NULL
.	NULL

Ohtani	NULL
,	NULL
K.	NULL
,	NULL
DeGregori	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
12146-12150	NULL
24	NULL
.	NULL

Geng	NULL
,	NULL
Y.	NULL
,	NULL
Eaton	NULL
,	NULL
E.	NULL
N.	NULL
,	NULL
Picon	NULL
,	NULL
M.	NULL
,	NULL
Roberts	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Lundberg	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Gifford	NULL
,	NULL
A.	NULL
,	NULL
Sardet	NULL
,	NULL
C.	NULL
&	NULL
Weinberg	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Oncogene	NULL
12	NULL
,	NULL
1173-1180	NULL
25	NULL
.	NULL

Means	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Slansky	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
McMahon	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Knuth	NULL
,	NULL
M.	NULL
W.	NULL
&	NULL
Farnham	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
1054-1063	NULL
26	NULL
.	NULL

Wade	NULL
,	NULL
M.	NULL
,	NULL
Kowalik	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Huang	NULL
,	NULL
E.	NULL
S.	NULL
&	NULL
Azizkhan	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4864-4374	NULL
27	NULL
.	NULL

Moberg	NULL
,	NULL
K.	NULL
,	NULL
Starz	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Lees	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
1486-1449	NULL
28	NULL
.	NULL

Smith	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Leone	NULL
,	NULL
G.	NULL
,	NULL
DeGregori	NULL
,	NULL
J.	NULL
,	NULL
Jakoi	NULL
,	NULL
L.	NULL
&	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
6965-6976	NULL
a	NULL
g	NULL
or	NULL
g	NULL
to	NULL
bo	NULL
is	NULL
0	NULL
w	NULL
g	NULL
~	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

Beijersbergen	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Carlee	NULL
,	NULL
L.	NULL
,	NULL
Kerkhoven	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Bernards	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
1840-1858	NULL
Buchkovich	NULL
,	NULL
K.	NULL
,	NULL
Duffy	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

&	NULL
Harlow	NULL
,	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
1097-1105	NULL
DeCaprio	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Ludlow	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Lynch	NULL
,	NULL
D.	NULL
,	NULL
Furukawa	NULL
,	NULL
Y.	NULL
,	NULL
Griffin	NULL
,	NULL
J.	NULL
,	NULL
Piwnica-Worms	NULL
,	NULL
H.	NULL
,	NULL
Huang	NULL
,	NULL
C.	NULL
M.	NULL
&	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
1085-1095	NULL
Mayol	NULL
,	NULL
X.	NULL
,	NULL
Garriga	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Grana	NULL
,	NULL
X	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Oncogene	NULL
11	NULL
,	NULL
801-808	NULL
Chen	NULL
,	NULL
P.	NULL
L.	NULL
,	NULL
Scully	NULL
,	NULL
P.	NULL
,	NULL
Shew	NULL
,	NULL
J.	NULL
Y.	NULL
,	NULL
Wang	NULL
,	NULL
J.	NULL
Y	NULL
.	NULL

&	NULL
Lee	NULL
,	NULL
W.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
1198-1198	NULL
Ewen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Sluss	NULL
,	NULL
H.	NULL
K.	NULL
,	NULL
Sherr	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Matsushime	NULL
,	NULL
H.	NULL
,	NULL
Kato	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
73	NULL
,	NULL
487-497	NULL
Kato	NULL
,	NULL
J.	NULL
,	NULL
Matsushime	NULL
,	NULL
H.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Ewen	NULL
,	NULL
M.	NULL
E.	NULL
&	NULL
Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
881-842	NULL
Qian	NULL
,	NULL
Y.	NULL
,	NULL
Luckey	NULL
,	NULL
C.	NULL
,	NULL
Horton	NULL
,	NULL
L.	NULL
,	NULL
Esser	NULL
,	NULL
M.	NULL
&	NULL
Templeton	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
5363-5372	NULL
Schwarz	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Devoto	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Smith	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Chellappan	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Jakoi	NULL
,	NULL
L.	NULL
&	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
1013-1020	NULL
Thomas	NULL
,	NULL
N.	NULL
S.	NULL
B.	NULL
,	NULL
Pizzey	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Tiwari	NULL
,	NULL
S.	NULL
,	NULL
Williams	NULL
,	NULL
C.	NULL
D.	NULL
&	NULL
Yang	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
28659-23667	NULL
Mayol	NULL
,	NULL
X.	NULL
,	NULL
Grana	NULL
,	NULL
X.	NULL
,	NULL
Baldi	NULL
,	NULL
A.	NULL
,	NULL
Sang	NULL
,	NULL
N.	NULL
,	NULL
Hu	NULL
,	NULL
Q	NULL
.	NULL

&	NULL
Giordano	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Oncogene	NULL
8	NULL
,	NULL
2561-2566	NULL
Sherr	NULL
,	NULL
C.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
1672-1677	NULL
Mudryj	NULL
,	NULL
M.	NULL
,	NULL
Devoto	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
Hiebert	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
Pines	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
1243-1253	NULL
Huet	NULL
,	NULL
X.	NULL
,	NULL
Rech	NULL
,	NULL
J.	NULL
,	NULL
Plet	NULL
,	NULL
A.	NULL
,	NULL
Vie	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Blanchard	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
3789-3798	NULL
Zwicker	NULL
,	NULL
J.	NULL
,	NULL
Liu	NULL
,	NULL
N.	NULL
,	NULL
Engeland	NULL
,	NULL
K.	NULL
,	NULL
Lucibello	NULL
,	NULL
F.	NULL
C.	NULL
&	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
271	NULL
,	NULL
1595-1597	NULL
Tommasi	NULL
,	NULL
S.	NULL
&	NULL
Pfeifer	NULL
,	NULL
G.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
6901-6913	NULL
Defrance	NULL
,	NULL
T.	NULL
,	NULL
Vanbervliet	NULL
,	NULL
B.	NULL
,	NULL
Durand	NULL
,	NULL
L.	NULL
,	NULL
Briolay	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Banchereau	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
2831-2839	NULL
Murphy	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

&	NULL
Norton	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
Leuk	NULL
.	NULL

Res	NULL
.	NULL

17	NULL
,	NULL
657-662	NULL
Darzynkiewicz	NULL
,	NULL
Z.	NULL
,	NULL
Crissman	NULL
,	NULL
H.	NULL
,	NULL
Traganos	NULL
,	NULL
F.	NULL
&	NULL
Steinkamp	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

118	NULL
,	NULL
465-474	NULL
Williams	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Linch	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Sorensen	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
La	NULL
Thangue	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

&	NULL
Thomas	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Br	NULL
.	NULL

J.	NULL
Haematol	NULL
.	NULL

96	NULL
,	NULL
688-696	NULL
Lam	NULL
,	NULL
E.	NULL
W.-F.	NULL
,	NULL
Choi	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
van	NULL
der	NULL
Sman	NULL
,	NULL
J.	NULL
,	NULL
Burbidge	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

&	NULL
Klaus	NULL
,	NULL
G.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
10051-10057	NULL
Mulligan	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Wong	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Jacks	NULL
,	NULL
T.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
206-220	NULL
Rogers	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
Higgins	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Milla	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Phillips	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Horowitz	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
7594-7599	NULL
Kelly	NULL
,	NULL
K.	NULL
,	NULL
Cochran	NULL
,	NULL
B.	NULL
H.	NULL
,	NULL
Stiles	NULL
,	NULL
C.	NULL
D.	NULL
&	NULL
Leder	NULL
,	NULL
P.	NULL
(	NULL
1983	NULL
)	NULL
Cell	NULL
35	NULL
,	NULL
603-610	NULL
Larsson	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
Gray	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Totterman	NULL
,	NULL
T.	NULL
,	NULL
Pettersson	NULL
,	NULL
U	NULL
.	NULL

&	NULL
Nilsson	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

84	NULL
,	NULL
228-227	NULL
Zetterberg	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
in	NULL
Apoptosis	NULL
and	NULL
Cell	NULL
Cycle	NULL
Control	NULL
in	NULL
Cancer	NULL
(	NULL
Thomas	NULL
,	NULL
N.	NULL
S.	NULL
B.	NULL
,	NULL
ed	NULL
)	NULL
pp	NULL
.	NULL

17-36	NULL
,	NULL
BIOS	NULL
Scientific	NULL
Publishers	NULL
Ltd.	NULL
,	NULL
Oxford	NULL
Williams	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Linch	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
Watts	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Thomas	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
90	NULL
,	NULL
194-203	NULL
Ikeda	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Jakoi	NULL
,	NULL
L.	NULL
&	NULL
Nevins	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
3215-3220	NULL
Bandara	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Lam	NULL
,	NULL
E	NULL
.	NULL

W.-F	NULL
'	NULL
.	NULL

,	NULL
Sorensen	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
Zamanian	NULL
,	NULL
M.	NULL
,	NULL
Girling	NULL
,	NULL
R.	NULL
&	NULL
La	NULL
Thangue	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

18	NULL
,	NULL
3104-3114	NULL
Belbrahem	NULL
,	NULL
A.	NULL
,	NULL
Godden-Kent	NULL
,	NULL
D.	NULL
&	NULL
Mittnacht	NULL
,	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Exp	NULL
.	NULL

Cell	NULL
Res	NULL
225	NULL
,	NULL
286-293	NULL
Evan	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Lewis	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
Ramsay	NULL
,	NULL
G.	NULL
&	NULL
Bishop	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

5	NULL
,	NULL
3610-3616	NULL
Thomas	NULL
,	NULL
N.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
13697-13700	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Modulation	NULL
of	NULL
E2F	NULL
Complexes	NULL
during	NULL
Go	NULL
to	NULL
S	NULL
Phase	NULL
Transition	NULL
in	NULL
Human	NULL
Primary	NULL
B-lymphocytes	NULL
Jeroen	NULL
van	NULL
der	NULL
Sman	NULL
,	NULL
N.	NULL
Shaun	NULL
B.	NULL
Thomas	NULL
and	NULL
Eric	NULL
W.-F.	NULL
Lam	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:12009-12016.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.17.12009	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/17/12009	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
59	NULL
references	NULL
,	NULL
31	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
7/1	NULL
2009.	NULL
full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

